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A B S T R A C T
Background
High-flow nasal cannulae (HFNC) deliver high flows of blended humidified air and oxygen via wide-bore nasal cannulae and may be
useful in providing respiratory support for adult patients experiencing acute respiratory failure in the intensive care unit (ICU).
Objectives
We evaluated studies that included participants 16 years of age and older who were admitted to the ICU and required treatment with
HFNC. We assessed the safety and efficacy of HFNC compared with comparator interventions in terms of treatment failure, mortality,
adverse events, duration of respiratory support, hospital and ICU length of stay, respiratory effects, patient-reported outcomes, and
costs of treatment.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 3), MEDLINE, the Cumulative Index to
Nursing and Allied Health Literature (CINAHL), Embase, Web of Science, proceedings from four conferences, and clinical trials
registries; and we handsearched reference lists of relevant studies. We conducted searches from January 2000 to March 2016 and reran
the searches in December 2016. We added four new studies of potential interest to a list of ‘Studies awaiting classification’ and will
incorporate them into formal review findings during the review update.
Selection criteria
We included randomized controlled studies with a parallel or cross-over design comparing HFNC use in adult ICU patients versus
other forms of non-invasive respiratory support (low-flow oxygen via nasal cannulae or mask, continuous positive airway pressure
(CPAP), and bilevel positive airway pressure (BiPAP)).
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Data collection and analysis
Two review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias.
Main results
We included 11 studies with 1972 participants. Participants in six studies had respiratory failure, and in five studies required oxygen
therapy after extubation. Ten studies compared HFNC versus low-flow oxygen devices; one of these also compared HFNC versus CPAP,
and another compared HFNC versus BiPAP alone. Most studies reported randomization and allocation concealment inadequately and
provided inconsistent details of outcome assessor blinding.Wedidnot combine data forCPAPandBiPAP comparisonswith data for low-
flow oxygen devices; study data were insufficient for separate analysis of CPAP and BiPAP for most outcomes. For the primary outcomes
of treatment failure (1066 participants; six studies) and mortality (755 participants; three studies), investigators found no differences
betweenHFNC and low-flow oxygen therapies (risk ratio (RR), Mantel-Haenszel (MH), random-effects 0.79, 95% confidence interval
(CI) 0.49 to 1.27; and RR,MH, random-effects 0.63, 95%CI 0.38 to 1.06, respectively).We used the GRADE approach to downgrade
the certainty of this evidence to low because of study risks of bias and different participant indications. Reported adverse events included
nosocomial pneumonia, oxygen desaturation, visits to general practitioner for respiratory complications, pneumothorax, acute pseudo-
obstruction, cardiac dysrhythmia, septic shock, and cardiorespiratory arrest. However, single studies reported adverse events, and we
could not combine these findings; one study reported fewer episodes of oxygen desaturation with HFNC but no differences in all other
reported adverse events. We downgraded the certainty of evidence for adverse events to low because of limited data. Researchers noted
no differences in ICU length of stay (mean difference (MD), inverse variance (IV), random-effects 0.15, 95% CI -0.03 to 0.34; four
studies; 770 participants), and we downgraded quality to low because of study risks of bias and different participant indications. We
found no differences in oxygenation variables: partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) (MD, IV,
random-effects 7.31, 95% CI -23.69 to 41.31; four studies; 510 participants); PaO2 (MD, IV, random-effects 2.79, 95% CI -5.47 to
11.05; three studies; 355 participants); and oxygen saturation (SpO2) up to 24 hours (MD, IV, random-effects 0.72, 95% CI -0.73
to 2.17; four studies; 512 participants). Data from two studies showed that oxygen saturation measured after 24 hours was improved
among those treated with HFNC (MD, IV, random-effects 1.28, 95% CI 0.02 to 2.55; 445 participants), but this difference was small
and was not clinically significant. Along with concern about risks of bias and differences in participant indications, review authors
noted a high level of unexplained statistical heterogeneity in oxygenation effect estimates, and we downgraded the quality of evidence
to very low. Meta-analysis of three comparable studies showed no differences in carbon dioxide clearance among those treated with
HFNC (MD, IV, random-effects -0.75, 95% CI -2.04 to 0.55; three studies; 590 participants). Two studies reported no differences
in atelectasis; we did not combine these findings. Data from six studies (867 participants) comparing HFNC versus low-flow oxygen
showed no differences in respiratory rates up to 24 hours according to type of oxygen delivery device (MD, IV, random-effects -1.51,
95% CI -3.36 to 0.35), and no difference after 24 hours (MD, IV, random-effects -2.71, 95% CI -7.12 to 1.70; two studies; 445
participants). Improvement in respiratory rates when HFNC was compared with CPAP or BiPAP was not clinically important (MD,
IV, random-effects -0.89, 95% CI -1.74 to -0.05; two studies; 834 participants). Results showed no differences in patient-reported
measures of comfort according to oxygen delivery devices in the short term (MD, IV, random-effects 0.14, 95% CI -0.65 to 0.93; three
studies; 462 participants) and in the long term (MD, IV, random-effects -0.36, 95% CI -3.70 to 2.98; two studies; 445 participants);
we downgraded the certainty of this evidence to low. Six studies measured dyspnoea on incomparable scales, yielding inconsistent study
data. No study in this review provided data on positive end-expiratory pressure measured at the pharyngeal level, work of breathing, or
cost comparisons of treatment.
Authors’ conclusions
We were unable to demonstrate whether HFNC was a more effective or safe oxygen delivery device compared with other oxygenation
devices in adult ICU patients. Meta-analysis could be performed for few studies for each outcome, and data for comparisons with CPAP
or BiPAP were very limited. In addition, we identified some risks of bias among included studies, differences in patient groups, and
high levels of statistical heterogeneity for some outcomes, leading to uncertainty regarding the results of our analysis. Consequently,
evidence is insufficient to show whether HFNC provides safe and efficacious respiratory support for adult ICU patients.
P L A I N L A N G U A G E S U M M A R Y
High-flow nasal cannulae for breathing support in adult intensive care patients
Background
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A common reason for intensive care unit (ICU) admission is the need for breathing (or respiratory) support. HFNC are small plastic
tubes that sit inside the nostrils and deliver a heated mix of air and oxygen at high flow rates to patients requiring breathing support.
They are used frequently in the ICU, yet no clear evidence shows whether they provide patients with long-term benefits such as reduced
ICU stay or improved chances of survival.
Study characteristics
The evidence is current to March 2016. We included in the review 11 studies with 1972 participants. Most participants had respiratory
failure, or had just been taken off an artificial breathing machine. Included studies compared HFNC with low-flow oxygen given
through face masks, through low-flow cannulae, or through devices that use mild pressure to aid oxygen delivery. We reran the search
in December 2016 and will deal with any studies of interest when we update the review.
Key results
We found no evidence that HFNC reduced the rate of treatment failure or risk of death compared with low-flow oxygen devices. We
found no evidence of any advantages for HFNC in terms of adverse event rates, ICU length of stay, or duration of respiratory support.
We observed no differences in participants’ blood oxygen levels or carbon dioxide blood levels, and we noted that any differences in
breathing rates were small and were not considered clinically important. Studies reported no differences in patient-rated measures of
comfort. Only one study found evidence of less dry mouth when HFNC was used.
Quality of evidence
Most studies had reported methods inadequately, and we did not know whether risk of bias may have affected study results. We
identified few eligible studies and noted some differences among participants within our included studies, particularly in reasons for
requiring respiratory support. We used the GRADE system to rate the evidence for each of our outcomes, and we judged all evidence
to be of low or very low quality.
Conclusion
We were not able to collect sufficient evidence from good quality studies to determine whether HFNC offer a safe and effective way of
delivering respiratory support for adults in the ICU.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
High- flow nasal cannulae versus low- flow oxygen for respiratory support in adult intensive care patients
Patient or population: adult intensive care pat ients requiring respiratory support
Settings: intensive care unit
Intervention: high-f low nasal cannulae (HFNC) vs low-f low oxygen
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Low- flow oxygen High- flow nasal
cannulae
Failure of treatment
as indicated by the
need for non- inva-
sive positive-pres-
sure ventilation or
invasive ventilation
236 per 1000 187 per 1000
(116 to 300)
RR 0.79
(0.49 to 1.27)
1066
(6 studies)
⊕⊕©©
lowa
In-hospital mortal-
ity up to 90 days
119 per 1000 74 per 1000
(44 to 123)
RR 0.62
(0.37 to 1.03)
755
(3 studies)
⊕⊕©©
lowb
Adverse events
Incidence of noso-
comial
pneumonia; visits to
GP for respiratory
complicat ions up to
day 28; episodes
of oxygen desatu-
rat ion; pneumotho-
rax, acute pseudo-
obstruct ion; cardiac
dysrhythmia; sept ic
See comment See comment Not est imable See comment ⊕⊕©©
lowc
Each adverse event
reported by indi-
vidual study au-
thors; therefore in-
suf f icient data for
pooling
4
H
ig
h
-fl
o
w
n
a
sa
l
c
a
n
n
u
la
e
fo
r
re
sp
ira
to
ry
su
p
p
o
rt
in
a
d
u
lt
in
te
n
siv
e
c
a
re
p
a
tie
n
ts
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
shock; cardiorespi-
ratory arrest
Length of ICU stay
in days
Mean length of stay
ranged f rom 1.39
days to 11.7 days
Mean length of
ICU stay in days
in the intervent ion
group was 0.15 days
longer than in the
control group
(0.03 shorter to 0.34
longer)
770 (5 studies) ⊕⊕©©
lowb
PaO2/ FiO2 ratio up
to 24 hours after ini-
tiation of therapy
Mean PaO2/ FiO2 ra-
t io ranged f rom 130
to 287.5
Mean PaO2/ FiO2 ra-
t io up to 24 hours af -
ter init iat ion of ther-
apy in the interven-
t ion group was 7.31
higher than in the
control group (23.
69 lower to 41.31
higher)
510
(4 studies)
⊕©©©
very lowd
Patient- re-
ported outcomes -
short- term comfort
Scale f rom 0 to 10
Mean scores ranged
f rom 1.11 to 5.2
Mean comfort score
in the intervent ion
group was 0.14
points higher (0.65
lower to 0.93 higher)
462 (3 studies) ⊕⊕©©
lowe
Patient- re-
ported outcomes -
long- term comfort
Scale f rom 0 to 10
Mean scores ranged
f rom 1.5 to 3.06
Mean comfort score
in the intervent ion
group was 0.36
points lower (3.70
lower to 2.98 higher)
445 (2 studies) ⊕⊕©©
lowf
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
aEvidence downgraded by two levels, as stat ist ical heterogeneity between studies was moderate, some studies had high or
unclear risk of bias, and some studies showed indirectness including part icipants requiring respiratory support for dif f erent
purposes
bEvidence downgraded by two levels, as some studies had high or unclear risk of bias in some domains and some studies
showed indirectness including part icipants requiring respiratory support for dif f erent purposes
cEvidence for each reported adverse event f rom single studies only. Not possible to combine in analysis; quality of data
downgraded by two levels for imprecision
dEvidence downgraded by three levels. Level of stat ist ical heterogeneity between studies (I2 = 86%) was substant ial;
indirectness, with studies including part icipants requiring respiratory support for dif f erent purposes, and very wide conf idence
intervals in the ef fect est imate
eEvidence downgraded by two levels: Ef fect est imate includes data f rom only three studies with some unclear risk of bias
within studies
f Evidence downgraded by three levels: Ef fect est imate includes data f rom only two studies with some unclear risk of bias
within studies and high level of stat ist ical heterogeneity
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B A C K G R O U N D
Description of the condition
Acute respiratory failure and the subsequent need for respiratory
support, is a frequent cause of admission of adults to an intensive
care unit (ICU) (Behrendt 2000). For such patients, respiratory
support is required owing to hypoxaemia, ventilatory failure, or
both (Shelly 1999). This respiratory support can be provided to
the patient in an invasive or non-invasive manner.
Invasive mechanical ventilation involves the insertion of an artifi-
cial airway (an endotracheal or tracheostomy tube). Although this
is regarded as a life-saving treatment, it comes with multiple in-
herent risks to patients. These risks include development of venti-
lator-induced lung injury (Gattinoni 2012), ventilator-associated
pneumonia (Muscadere 2008), neurocognitive sequelae associated
with prolonged sedation (Morandi 2011; Nelson 2000), and in-
creased length of ICU and hospital stay (Safdar 2005). When pos-
sible, therefore, invasivemechanical ventilation should be avoided,
although intubation and mechanical ventilation are inevitable if
the patient has stopped breathing or is unable to maintain his or
her airway (Nava 2009).
Non-invasive respiratory support, when possible, is the preferred
method of respiratory support and can be delivered via any of the
following approaches.
• Low-flow nasal cannulae (LFNC).
• Simple face mask.
• Venturi mask.
• Non-rebreather mask.
• Non-invasive positive-pressure ventilation (NIPPV).
• High-flow nasal cannulae (HFNC).
The type of delivery device chosen depends largely on the severity
and the cause of the patient’s acute respiratory failure, and each
device provides benefits and drawbacks that determine its useful-
ness in clinical practice.
Physicians use LFNC for patients requiring minimal respiratory
support in the form of supplemental oxygen to maintain adequate
oxygenation. These cannulae deliver dry oxygen at 1 to 6 litres
per minute via small prongs approximately 1.5 cm long, which sit
just inside the nares of the nose (O’Driscoll 2008). Although they
are generally well tolerated by patients (Zevola 2001), delivery of
higher flows of oxygen through LFNC is not practicable owing
to the drying and irritating effects of cold dry gas on the mucosa
(Lellouche 2002).
Delivery of oxygen via a face mask is necessary if the patient has
higher oxygen requirements than can be achieved with LFNC.
Simple face masks can deliver 5 to 10 litres per minute of oxy-
gen. For patients requiring increased oxygen and higher flows to
maintain adequate oxygenation, non-rebreather masks can deliver
10 to 15 litres per minute of oxygen (O’Driscoll 2008). Oxygen
may be supplemented with humidification by some devices. Sim-
ple face masks and non-rebreather masks are capable of delivering
relatively high oxygen concentrations; therefore they are generally
unsuitable for patients with chronic obstructive pulmonary dis-
ease (COPD), who may retain carbon dioxide. For hypercapnoeic
patients with COPD, oxygen concentration can be regulated by a
Venturi mask, which can deliver between 24% and 60% oxygen
at a flow of 2 to 15 litres per minute (O’Driscoll 2008). Although
face masks are effective for delivering oxygen to patients with mild
to moderate acute respiratory failure, they can be poorly tolerated
when compared with nasal cannulae owing to discomfort and feel-
ings of claustrophobia, leading to reduced compliance as a result of
frequent removal and subsequent treatment interruption (Sasaki
2003).
NIPPV can be used in patients who not only require supplemen-
tal oxygen but also need support for the mechanical process of
ventilation (Mehta 2001). A blend of oxygen and air is delivered
at a prescribed fraction of inspired oxygen (FiO2) via a tight-fit-
ting mask (nasal mask, oronasal mask, or full face mask). Addi-
tionally, continuous positive airway pressure (CPAP) or bilevel
positive airway pressure ventilation (BiPAP) is delivered to im-
prove alveolar recruitment, improve gas exchange, and decrease
the work of breathing (Mehta 2001). Although CPAP is not a
true ventilatory mode, it is often referred to as NIPPV in clinical
practice (Nava 2009). Substantial available data show that NIPPV
improves outcomes among patients requiring respiratory support
owing to cardiogenic pulmonary oedema or acute exacerbations of
COPD, and also among patients weaning from invasive mechan-
ical ventilation (Nava 2009). However, its relevance for patients
with hypoxaemic acute respiratory failure is less clearly defined
(Nava 2009). Despite showing clear benefit for certain conditions,
NIPPV inhibits mobilization, is associated with gastric distension,
restricts effective communication and oral nutrition, and is poorly
tolerated by some patients owing to discomfort (Gregoretti 2002;
Mehta 2001).
Although the conventional non-invasive delivery devices listed
above provide important therapies in the range of respiratory sup-
port available to treat patients with acute respiratory failure, it is
evident that they have limitations that can impact their usefulness
in clinical practice. Failure of these devices to provide adequate
respiratory support and to correct acute respiratory failure often
results in the need for required intubation and mechanical venti-
lation.
Description of the intervention
HFNC, which have been used in the neonatal setting for some
years (Wilkinson 2011), are a relatively new method of delivering
respiratory support to adults experiencing acute respiratory failure.
Cannulae are approximately 1.5 cm long and 0.5 cm in diameter
and, as with LFNC, sit just inside the nares. A gas flow of up to
60 litres per minute can be delivered because the gas is warmed
and humidified, making it less irritating to the nasal mucosa. For
the purposes of this review, HFNC will be defined as humidified
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oxygen delivered via nasal cannulae at a rate greater than 20 litres
per minute. Very few adverse reactions have been reported with
HFNC use, and those reported consist of minor complaints of a
runny nose (Price 2008) and some discomfort with heat or flow
rate (Roca 2010).
How the intervention might work
HFNC can deliver blended humidified air and oxygen via wide-
bore nasal cannulae at a prescribed FiO2 at high flow rates. HFNC
do not need to be removed during oral hygiene care or when
patients talk, eat, or drink, resulting in less frequent interruptions
to therapy. In the growing body of evidence gathered when effects
of HFNC are investigated, improvements in oxygenation (Corley
2011; Parke 2009; Roca 2010; Sztrymf 2011; Sztrymf 2011a),
respiratory rate (Corley 2011; Roca 2010; Sztrymf 2011; Sztrymf
2011a), dyspnoea (Corley 2011; Roca 2010; Sztrymf 2011), and
patient comfort (Corley 2011; Roca 2010; Tiruvoipati 2010) have
been reported in recent observational studies.
Suggested mechanisms of action of HFNC consist of:
• flushing of anatomical dead space due to high gas flow,
functionally reducing dead space and improving respiratory
efficiency (Dysart 2009);
• generation of positive airway pressure (Corley 2011; Groves
2007; Parke 2009), which increases functional residual capacity
and improves alveolar recruitment;
• improved ability to meet high inspiratory flow demands
among patients requiring respiratory support and to deliver a
more accurate FiO2 through less dilution by entrainment of
room air (Dysart 2009); and
• ability to deliver optimal humidification, leading to
enhanced mucociliary transport (Salah 1988) and improved
patient comfort (Chanques 2009).
We conducted this review to compare the efficacy and safety of
HFNC versus other methods of non-invasive respiratory support
in adult patients admitted to the ICU.
Why it is important to do this review
It has been demonstrated that HFNC offer some immediate phys-
iological benefit for patients requiring respiratory support, but it
remains to be determined whether they offer any clinically impor-
tant benefit and improve patient outcomes, such as by preventing
progression to invasive mechanical ventilation and reducing mor-
tality. Individual studies may tend to focus on surrogate outcomes
or may be underpowered to detect effects on clinically important
outcomes. By performing this review, we can extract data on im-
portant clinical outcomes and can conduct meta-analyses on ef-
fects of the intervention on these outcomes with greater statistical
power to detect meaningful patient differences should they exist.
AsHFNCgain in popularity as a treatmentmodality for providing
respiratory support, it is important to perform this review to syn-
thesize the existing evidence base and to provide clear conclusions
regarding the efficacy and safety of HFNC. In this way, clinicians
canmake decisions about how this form of respiratory support can
best be incorporated into the current suite of treatment options;
and for whom this treatment can be used most efficaciously.
O B J E C T I V E S
We evaluated studies that included participants 16 years of age and
older who were admitted to the ICU and required treatment with
HFNC. We assessed the safety and efficacy of HFNC compared
with comparator interventions in terms of treatment failure, mor-
tality, adverse events, duration of respiratory support, hospital and
ICU length of stay, respiratory effects, patient-reported outcomes,
and costs of treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomized, parallel, and quasi-randomized stud-
ies (including cross-over studies) that compared HFNC versus
other forms of non-invasive respiratory support for selected out-
come measures. We included quasi-randomized trials in this re-
view owing to the current scarcity of randomized controlled trials
(RCTs) in this area.
Owing to the inability of randomized cross-over studies to detect
long-term patient outcomes, we included this trial design only
for the secondary outcome measures of positive end-expiratory
pressure, oxygenation, carbon dioxide clearance, respiratory rate,
work of breathing, and patient-reported outcomes.
We did not impose a language restriction, and we considered stud-
ies written in any language.
We excluded retrospective studies and prospective cohort or obser-
vational studies, as we wanted to focus on evidence of the highest
quality from randomized studies.
Types of participants
We included studies that enrolled adult patients (16 years of age
or older) requiring respiratory support and admitted to the ICU.
We excluded participants younger than 16 years of age. Two al-
ready published Cochrane reviews have assessed the effectiveness
of HFNC in preterm infants (Wilkinson 2011) and in the paedi-
atric population (Mayfield 2012).
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We also excluded patients not admitted to an ICU.
Types of interventions
We included humidified oxygen delivered via the nasal route at a
rate greater than 20 litres per minute as the experimental inter-
vention.
We included the following forms of non-invasive respiratory sup-
port as comparison interventions.
• Low-flow oxygen via nasal cannulae or mask (≤ 15 litres
per minute).
• Continuous positive airway pressure (CPAP).
• Bilevel positive airway pressure (BiPAP).
Types of outcome measures
The outcome measures in this review are a mix of surrogate and
clinical outcomes. We recognize that while there may be a correla-
tion between the surrogate and clinical outcomes, it is the clinical
outcomes which will provide the strongest evidence regarding the
safety and efficacy of HFNC. As a result, we chose the clinical out-
come of failure of treatment as indicated by the need for NIPPV
or invasive ventilation as one of our primary outcome measures
Primary outcomes
1. Treatment failure as indicated by the need for NIPPV or
invasive ventilation (up to 28 days)
2. In-hospital mortality (up to 90 days)
3. Adverse events
Secondary outcomes
1. Duration in hours of any form of respiratory support (mechan-
ical ventilation, NIPPV, HFNC, standard oxygen)
2. Length of stay in days (ICU and hospital)
3. Respiratory effects as indicated by any of the following
• Degree of atelectasis on radiological examination
• Positive end-expiratory pressure measured at the pharyngeal
level (cm H2O)
• Oxygenation (partial pressure of arterial oxygen (PaO2)/
fraction of inspired oxygen (FiO2) ratio, PaO2, oxygen saturation
of arterial blood (SaO2), and oxygen saturation (SpO2))
• Carbon dioxide clearance (partial pressure of carbon
dioxide in arterial blood (PaCO2) and partial pressure of carbon
dioxide (PCO2))
• Respiratory rate
• Work of breathing (joules per litre)
4. Patient-reported outcomes as indicated by any of the following
• Dyspnoea
• Comfort
• Dry mouth
• Patient refusal to continue with treatment
5. Cost comparison of treatment (in Australian dollars)
We assessed all outcomes at the time points reported in included
studies. For patient-reported outcomes, we accepted study authors’
definitions.
Search methods for identification of studies
Electronic searches
We searched the following databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (2016, Issue 3); see
Appendix 1.
• MEDLINE, OvidSP (January 2000 to March 2016); see
Appendix 2.
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL), EBSCOhost (January 2000 to March 2016); see
Appendix 3.
• Embase, OvidSP (January 2000 to March 2016); see
Appendix 4.
• Institute for Scientific Information (ISI) Web of Science
(January 2000 to March 2016); see Appendix 5.
We restricted the search start date to 2000, as HFNC have been
available for use in the adult population only since the mid-2000s.
We adapted theMEDLINE search strategy for searches of all other
databases.
We (Amanda Corley (AC)) searched for published abstracts from
conference proceedings for the European Society of Intensive Care
Medicine, the Australia and New Zealand Intensive Care Society,
the Society of Critical Care Medicine, and the American Thoracic
Society (2000 to May 2014).
For trials not yet completed, we searched clinical trials reg-
istries (clinicaltrials.gov; controlled-trials.com; anzctr.org.au; and
who.int/ictrp). We (AC) contacted trial authors to determine
whether any data were available for inclusion in the review; how-
ever, we received no responses.
We reran database searches in December 2016. We added new
studies of potential interest to Characteristics of studies awaiting
classification andwill incorporate them into formal reviewfindings
during the review update.
Searching other resources
We screened the reference lists of eligible trials to identify any
previously unidentified studies.
Data collection and analysis
Selection of studies
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We included in the review all randomized, parallel-group, and
quasi-randomized controlled trials (including randomized cross-
over trials) meeting review criteria. Two review authors (of AC,
ClaireMRickard (CMR), SharonRLewis (SRL), AndrewF Smith
(AFS)) independently examined published titles and abstracts ob-
tained during the search and screened them for suitability. Each
review author completed a study selection form (see Appendix 6),
and if the study was to be excluded, we detailed the reasons for
exclusion. All review authors reached consensus regarding study
inclusion.
Data extraction and management
Two review authors (of AC, CMR, SRL, AFS) independently
extracted data from each study onto the data extraction form
(see Appendix 7) and compared data extraction forms for each
study. Review authors reached consensus regarding extracted data
through discussion.
Assessment of risk of bias in included studies
Two review authors (of AC, CMR, SRL, AFS) independently as-
sessed the risk of bias of each study. Review authors reported no
disagreements regarding assessment of risk of bias. We (AC) con-
tacted some trial authors if we needed more information to assess
risk of bias.
We conducted assessment of risk of bias in included studies by
using the ‘Risk of bias’ tool, as per the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011), using the quality
assessment form (see Appendix 8).We assessed trials as having low
risk of bias if we assessed all of the following areas as adequate. We
assessed trials as having high risk of bias if we assessed one or more
of these areas as not adequate or unclear.
We assessed risk of bias in the following domains.
Random sequence generation (selection bias)
We assessed allocation of interventions as adequate if allocation
was performed in a truly unpredictable manner (e.g. computer-
ized random number generator, random number table, shuffled
envelope system, coin toss, roll of the die).
We assessed allocation as inadequate if it was based on non-ran-
dom methods (e.g. day of the week, alternate patients, patient
characteristics such as date of birth, hospital identifier) or if the
method of allocation was unclear.
Allocation concealment (selection bias)
We assessed allocation concealment as adequate if study person-
nel and participants were unaware of the treatment allocation of
the next participant (e.g. central or telephone randomization, se-
quentially numbered sealed opaque envelopes, on-site computer
accessed only after patient enrolment).
Inadequate allocation concealment included randomizationmeth-
ods deemed inadequate above (e.g. unsealed or non-sequential en-
velopes, open allocation sequence) or unclear methods of alloca-
tion concealment.
Blinding of outcome assessors (performance and detection
bias)
It is not possible to blind the participant or the clinical staff to
treatment allocation for this intervention; therefore, we limited
assessment of risk of bias to blinding of outcome assessors. For
interventions such as oxygen delivery devices for which it is not
possible to blind participants or clinical staff, some performance
bias is inevitable.
We assessed blinding as adequatewhenoutcome assessorswere def-
initely blinded to treatment allocation. If blinding was not men-
tioned, we deemed blinding as not adequate.
When blinding of outcome assessors was not always possible (e.g.
respiratory rate, oxygenation, carbon dioxide clearance, work of
breathing), we assessedwhether this would have been likely to have
introduced bias. If measurement of the outcome was unlikely to
have been influenced by lack of blinding, we assumed that blinding
was adequate.
When the participant was the outcome assessor (i.e. for patient-
reported outcomes), we deemed blinding as adequate if strategies
to reduce potential bias were evident (e.g. standardized question-
ing strategy used for all patient-reported outcomes, questioning
carried out by non-study staff ).
Incomplete outcome data, intention-to-treat (attrition bias)
We deemed outcome data as adequate if all withdrawals, protocol
deviations, and losses to follow-up were reported and incomplete
data were proportionate across groups. If this was not reported,
we assessed outcome data as inadequately dealt with.
Selective reporting
We assessed outcome reporting as adequate if all previously stated
outcomes were fully reported. We assessed outcome reporting as
inadequate if all previously stated outcomes were not reported, if
outcomes were not fully reported, or if outcomes were reported
but were not previously mentioned.
Measures of treatment effect
We performed statistical analyses using Review Manager 5 (
RevMan 5.3). We expressed dichotomous data as risk ratio (RR),
risk difference (RD), and number needed to treat for an additional
beneficial outcome (NNTB).We expressed continuous data as the
difference betweenmeans.We reported the 95% confidence inter-
val (CI) for all estimates. We treated ordinal data (e.g. mouth dry-
ness on a scale of 0 to 10) as continuous data. To cope with non-
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normally distributed data, we used the generalized linear model
framework while assuming a gamma distribution.
Unit of analysis issues
The unit of analysis for all included studies was the participant,
and our meta-analysis was based on summary statistics derived
from participant level data.
We identified three cross-over trials as eligible for inclusion
(Chanques 2013; Rittayamai 2014; Schwabbauer 2014). The
study author for one study (Schwabbauer 2014) did not report
data for the first cross-over period; therefore, we included no data
from this study in the analysis. Study authors from the other two
studies (Chanques 2013; Rittayamai 2014) provided data from
the first treatment period for inclusion in the review.
Included studies measured many of the secondary outcomes (oxy-
genation (PaO2, PaO2/FiO2 ratio, SpO2), carbon dioxide clear-
ance, respiratory rate, dyspnoea, mouth dryness, and patient com-
fort) at multiple time points. To overcome the potential for unit
of analysis error, we took a simple approach to analysis of these
outcomes on the advice of the statistical editor. We reported out-
come data as short-term and longer-term effects, with short-term
effects resulting from initiation of therapy up to 24 hours, and
longer-term effects occurring more than 24 hours after initiation
of therapy. For short-term effects, we used the closest data point
to 24 hours. Only two studies (Maggiore 2014; Parke 2013a) as-
sessed outcomes for longer than 24 hours. Both studies measured
outcomes at 48 hours after initiation of therapy; therefore, we used
this time point as the longest follow-up data.
We identified two studies that had three arms (Frat 2015;
Schwabbauer 2014). Both comparison arms were relevant for this
review. We included no data for Schwabbauer 2014, as stated
above. For Frat 2015, we used the halving method (as described by
Higgins 2011) to divide dichotomous data for the HFNC group
equally for each comparison group. It was not possible to do this
for continuous data; therefore, we included only the comparison
arm that gave the most conservative estimate for each outcome.
Dealing with missing data
We contacted some study authors via email for further information
regarding study methods and data. Study authors did not iden-
tify missing data in addition to those reported in the published
review, and we were unable to tabulate missing data and perform
sensitivity analyses to determine the influence of missing data on
effect estimates, as planned in the protocol.
Assessment of heterogeneity
Using clinical judgement, we assessed participants, interventions,
and outcomes for clinical heterogeneity.We assessed methodolog-
ical heterogeneity during risk of bias assessments and by visual
inspection of forest plots. We assessed statistical heterogeneity by
using the I2 statistic (on a scale of 0% to 100%) and the Chi2 test
(Higgins 2011).
Assessment of reporting biases
As fewer than 10 trials were available for the meta-analysis, we did
not assess publication bias in this review.
Data synthesis
We conducted meta-analyses for outcomes for which we had com-
parable study data. We performed separate analyses for compar-
isons of low-flow oxygen devices and for comparisons of CPAP
and BiPAP. If studies selected for inclusion did not have moderate
to substantial levels of heterogeneity (clinical, methodological, or
statistical), we would have used a fixed-effect model to calculate
effects estimates. We classified the level of heterogeneity using the
I2 statistic as 0% to 40% not important; 30% to 60% moderate
heterogeneity; 50% to 90% substantial heterogeneity; and 75%
to 100% considerable heterogeneity (Higgins 2011). We selected
a random-effects model, rather than a fixed-effect model, owing
to heterogeneity and overall small sample sizes for our outcome
data. We conducted analyses for outcomes using Review Manager
5 (RevMan 5.3).
Subgroup analysis and investigation of heterogeneity
We performed subgroup analysis for studies that included par-
ticipants requiring respiratory support for respiratory failure and
participants requiring respiratory support after extubation.
Sensitivity analysis
To determine the sensitivity of findings to the way in whichwe had
conducted the analysis, we performed sensitivity analysis based
on risk of bias judgements and statistical models used for effect
estimates.
Summary of findings table and GRADE
We used the principles of the GRADE system (Guyatt 2008) to
assess the quality of the body of evidence associated with the spe-
cific outcomes listed below.
• Failure of treatment as indicated by the need for NIPPV or
invasive ventilation.
• In-hospital mortality.
• Adverse events.
• Length of stay in days (ICU).
• PaO2/FiO2 ratio up to 24 hours after initiation of therapy.
• Patient-reported outcomes - comfort over the short term.
• Patient-reported outcomes - comfort over the long term.
We constructed a ’Summary of findings’ table using GRADE soft-
ware as a guide. The GRADE approach appraises the quality of a
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body of evidence on the basis of the extent to which one can be
confident that an estimate of effect or association reflects the item
being assessed. The quality of a body of evidence considers within-
study risk of bias (methodological quality), directness of the evi-
dence, heterogeneity of the data, precision of effect estimates, and
risk of publication bias. See Summary of findings for the main
comparison.
R E S U L T S
Description of studies
See Characteristics of included studies, Characteristics of excluded
studies, and Characteristics of ongoing studies.
Results of the search
We conducted electronic searches in May 2014, May 2015, and
March 2016. We identified 2773 records, and by handsearching
reference lists, we identified another 30 records. From these re-
sults, we identified 43 reports for which we sourced the full text
and assessed eligibility against our review inclusion criteria. We
found 11 studies, three of which provided six additional associated
references. We were unable to classify two studies without further
information, and we excluded 24 studies. See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
We included 11 RCTs with 1972 randomized participants; eight
used a parallel design (Corley 2014; Cuquemelle 2012; Frat 2015;
Lemiale 2015;Maggiore 2014; Parke 2011; Parke 2013a; Stephan
2015), and three were randomized cross-over studies (Chanques
2013; Rittayamai 2014; Schwabbauer 2014). We were unable to
gain data from one RCT for the outcomes of interest, so we in-
cluded only narrative results (Cuquemelle 2012). This study in-
cluded a four-hour cross-over period at the end of a 24-hour par-
allel assignment period; therefore we included in this review only
narrative results from the initial 24-hour period. One of the ran-
domized cross-over studies provided no data from the first treat-
ment period (as per the review protocol, only data from the first
treatment period were to be included in the review) (Schwabbauer
2014). Therefore, we were unable to include in the review any
data from study authors’ reported outcomes (oxygenation, patient-
reported dyspnoea, and patient-reported comfort). We included
data from seven RCTs (Corley 2014; Frat 2015; Lemiale 2015;
Maggiore 2014; Parke 2011; Parke 2013a; Stephan 2015) and data
from the first treatment period of two randomized cross-over stud-
ies (Chanques 2013; Rittayamai 2014) in the meta-analysis when
applicable. Two review authors achieved complete agreement on
study inclusion. We provided details of each of the included stud-
ies (inclusion and exclusion criteria, intervention details, reported
outcomes, study dates, country, setting, funding sources, and dec-
larations of interest) in the Characteristics of included studies ta-
ble.
We included only studies that examined participants 16 years
of age or older who were patients in the ICU requiring respi-
ratory support. Participants in five studies had respiratory fail-
ure (Cuquemelle 2012; Frat 2015; Lemiale 2015; Parke 2011;
Schwabbauer 2014), those in Stephan 2015 were at risk of acute
respiratory failure, and those in the remaining five studies were
given oxygen therapy after extubation (Chanques 2013; Corley
2014; Maggiore 2014; Parke 2013a; Rittayamai 2014). Partici-
pants in Corley 2014 had a body mass index (BMI) of at least 30
kg/m2. No other studies included or excluded participants on the
basis of BMI.
All included studies used the Optiflow HFNC system (Fisher &
Paykel Healthcare) to deliver humidified high-flow nasal oxygen.
By contacting the study authors listed below, we confirmed flow
rates for the intervention group as between 35 and 50 litres per
minute for five studies (Cuquemelle 2012; Maggiore 2014; Parke
2011; Parke 2013a; Rittayamai 2014). Some study authors re-
ported flow rates up to a maximum of 50 L/min (Corley 2014;
Frat 2015; Lemiale 2015; Stephan 2015). Schwabbauer 2014 re-
ported flow rates at 55 L/min. Chanques 2013 tested each oxygen
delivery device at 15, 30, and 45 L/min.
Three studies included two comparison groups (Chanques 2013;
Frat 2015; Schwabbauer 2014). Comparisons with face masks
used a simple facemask, nasal cannulae, a non-rebreather facemask
orVenturimask (Corley 2014; Frat 2015; Lemiale 2015;Maggiore
2014; Parke 2013a; Rittayamai 2014; Schwabbauer 2014), a high-
flow face mask (Chanques 2013), and a high-flow face mask with
humidifier (Parke 2011). Comparisons with NIPPV devices used
Bossignac oxygen therapy (Chanques 2013) and bilevel positive
airway pressure (BiPAP) (Stephan 2015), and two studies pro-
vided non-invasive ventilation (Frat 2015; Schwabbauer 2014).
Cuquemelle 2012) described as the use of ’standard oxygen ther-
apy’. All comparisons included low-flow oxygen delivery at ≤ 15
L/min. Chanques 2013 included comparisons with oxygen flow
at 15, 30, and 45 L/min, but we included data only for the 15 L/
min group.
We contacted eight study authors by email to request additional
details, including outcome data not available in the published re-
port and information for risk of bias assessment (Chanques 2013;
Corley 2014; Cuquemelle 2012; Maggiore 2014; Parke 2011;
Parke 2013a; Rittayamai 2014; Schwabbauer 2014). Chanques
2013, Corley 2014, Parke 2011, Parke 2013a, and Rittayamai
2014 provided participant and outcome data and clarification
on methodological issues; Cuquemelle 2012 provided informa-
tion on methodological issues but was unable to provide data;
Schwabbauer 2014 was unable to provide any additional details
of this study. Following contact with Maggiore 2014, the full re-
port was published, and we used data from this report, rather than
information provided via email communication.
Excluded studies
We excluded 24 studies during full-text review and provided rea-
sons for exclusion for nine key trials (Baneton 2014; Besch 2014;
Braunlich 2013; Curley 2015; Parke 2013b; Pinto 2012; Simon
2014; Tiruvoipati 2010; Vourc’h 2015). Further investigation re-
vealed that three trials were not RCTs (Baneton 2014; Besch 2014;
Curley 2015); two trials did not include participants of interest
(Braunlich 2013; Pinto 2012); one trial did not measure outcomes
of interest (Parke 2013b); two trials assessed oxygen therapy for
different procedures (during flexible bronchoscopy, Simon 2014;
and with pre-oxygenation before intubation, Vourc’h 2015); and
in one trial, the comparison intervention did not meet the review
criteria (Tiruvoipati 2010). SeeCharacteristics of excluded studies.
Studies awaiting classification
We were unable to assess eligibility for two studies, which were
published as abstracts (Perbet 2014; Saeed 2015). We reran the
search in December 2016 and identified four studies for poten-
tial inclusion (Futier 2016; Hernandez 2016a; Hernandez 2016b;
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Lemiale 2016). We will incorporate these into formal review
findings during the review update. See Characteristics of studies
awaiting classification for additional details.
Ongoing studies
We identified nine on-
going studies (NCT01166256; NCT01820507; NCT01994928;
NCT01702779; NCT01782430; NCT02123940;
NCT02107183; UMIN000008778; NCT01617252). See
Characteristics of ongoing studies for details.
Risk of bias in included studies
We detailed risks of bias for the included studies in the ’Risk of
bias’ tables in Characteristics of included studies, the ’Risk of bias’
graph (Figure 2), and the ’Risk of bias’ summary (Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We judged that seven studies used an appropriate method of ran-
domization to allocate participants, for example, a block system, a
computer-generated sequence, or an external randomization ser-
vice (Corley 2014; Frat 2015; Lemiale 2015; Maggiore 2014;
Parke 2011; Parke 2013a; Stephan 2015); three of these also re-
ported adequate methods of concealing allocation (Corley 2014;
Lemiale 2015; Parke 2013a). Other studies failed to provide suffi-
cient information; therefore, it was unclear whether these studies
were at risk of selection bias.
Blinding
Owing to the nature of the intervention and comparators, it is
not possible to blind participants and their treating clinicians to
treatment allocation. Subsequently, some of the included studies
(Chanques 2013; Cuquemelle 2012;Maggiore 2014; Parke 2011;
Parke 2013a; Rittayamai 2014) stated that participants and treat-
ing clinicians were not blinded to treatment allocation, and we
assumed that no blinding occurred in the remaining studies. We
believe that knowledge of treatment would not influence perfor-
mance for the outcomes of interest for this review; we therefore
judged all studies to have low risk of performance bias.
Participants were the outcome assessors in studies that exam-
ined patient-reported outcomes (Chanques 2013; Corley 2014;
Cuquemelle 2012; Frat 2015; Lemiale 2015; Maggiore 2014;
Parke 2013a; Rittayamai 2014; Stephan 2015). However, we be-
lieve that the inability to blind participants to treatment allocation
would not affect outcome measurements because it would be un-
likely that participants would have a particular bias towards one
medical intervention over another. Cuquemelle 2012 measured
only patient-reported outcomes; therefore we judged this study to
have low risk of detection bias overall. For other studies, which
included both patient-reported and clinician-reported outcomes,
we considered the impact of clinician knowledge of participant
group allocation. In Corley 2014 and Parke 2013a, outcome asses-
sors for atelectasis were blinded to treatment allocation; therefore
we judged these studies to have low risk of detection bias for these
outcomes. However, for other outcomes and for other studies in
which this information was not provided, it was unclear whether
risk of detection bias was increased and what impact this may have
had on the results.
Incomplete outcome data
We judged three studies to have low risk of attrition bias with
outcome data fully reported for all participants (Corley 2014;
Maggiore 2014; Stephan 2015). Schwabbauer 2014 used an inten-
tion-to-treat analysis, and we were satisfied that this represented
low risk of bias. Frat 2015, Lemiale 2015, and Parke 2013a re-
ported a small number of losses, and we judged these studies to
have low risk of attrition bias. Chanques 2013 and Parke 2011 pro-
vided insufficient detail to allow judgement of whether losses had
been adequately handled, and Rittayamai 2014 did not provide
details on losses or numbers of participants analysed. Cuquemelle
2012 reported a high number of losses (seven losses out of 37 ran-
domized participants), and we judged this study to have high risk
of bias.
Selective reporting
Nine studies reported clinical trial registration (Chanques 2013;
Corley 2014; Frat 2015; Lemiale 2015; Maggiore 2014; Parke
2011; Parke 2013a; Schwabbauer 2014; Stephan 2015). Five were
prospectively registered, and we were able to compare a priori
outcomes stated in clinical trials registration protocols, alongside
outcomes measured and reported in completed published studies;
three trials reported outcomes according to the study protocol
(Corley 2014; Frat 2015; Stephan 2015), and we judged these
studies to have low risk of reporting bias, but two studies reported
additional outcomes (Parke 2011; Parke 2013a), and we therefore
judged these studies to have high risk of bias for this domain.
Four studies were retrospectively registered (Chanques 2013;
Lemiale 2015; Maggiore 2014; Schwabbauer 2014). Of these,
Maggiore 2014 was registered shortly after the beginning of re-
cruitment, and as a priori outcomes matched reported outcomes,
we judged this study to have low risk of reporting bias. It was
not feasible for us to compare protocols against completed studies
for the remaining retrospectively registered studies; therefore, we
could not judge bias for this domain. Two studies did not report
trial registration; therefore, we also were not able to judge these
studies (Cuquemelle 2012; Rittayamai 2014).
Other potential sources of bias
Todate, one of the included studies (Maggiore 2014) has presented
three abstracts, and this study is part of a larger ongoing clinical
trial (see NCT02107183 in Characteristics of ongoing studies).
Multiple interim analyses could introduce bias (Bland 1995).
One study (Cuquemelle 2012) reported potentially clinically rele-
vant baseline imbalances between groups, with participants in the
intervention group being older (median 66 years vs 51 years of
age) and having a higher rate of infectious pneumonia (57% vs
33%).
For cross-over studies, we included data only from the first treat-
ment period. Therefore, lack of a washout period or descrip-
tion of treatment during the washout period in Chanques 2013,
Cuquemelle 2012, and Rittayamai 2014 did not introduce risk of
bias for this review.
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Participants in theNIPPV group in Frat 2015 usedHFNC during
breaks in delivery of oxygen. We judged this study to have high
risk of bias as a result of this methodological decision.
Nine studies declared funding or provision of equipment from
manufacturers of the HFNC system (Fisher & Paykel Healthcare)
(Chanques 2013; Corley 2014; Cuquemelle 2012; Frat 2015;
Lemiale 2015; Maggiore 2014; Parke 2011; Parke 2013a;
Schwabbauer 2014). Six of these reported that the manufacturer
had not been involved in study design,management, or data analy-
ses, and we considered these studies to have low risk of bias (Corley
2014; Cuquemelle 2012; Frat 2015; Lemiale 2015; Parke 2013a;
Schwabbauer 2014); two of these six did not report involvement
of the manufacturer, and we were unclear whether this funding
represented risk of bias (Chanques 2013; Maggiore 2014); one
study reported that the manufacturer had been involved in the
study design and had paid for statistical analysis; we judged this
study to have high risk of bias (Parke 2011).
Effects of interventions
See: Summary of findings for the main comparisonHigh-flow
nasal cannulae versus low-flow oxygen for respiratory support in
adult intensive care patients
See Summary of findings for the main comparison.
Primary outcomes
1. Failure of treatment as indicated by the need for NIPPV
or invasive ventilation
Eight studies reported failure of treatment (Corley 2014;
Cuquemelle 2012; Frat 2015; Lemiale 2015; Maggiore 2014;
Parke 2011; Parke 2013a; Stephan 2015). Cuquemelle 2012 re-
ported less treatment failure associated with HFNC, with one of
19 participants in the HFNC group failing treatment compared
with four of 18 participants in the low-flow oxygen group. How-
ever, we were unable to include these data in the meta-analysis, as
we could not confirm with study authors if these failures occurred
during the initial 24-hour parallel period or during the final four-
hour cross-over period. We did not combine Stephan 2015 in the
meta-analysis, as the comparison group (BiPAP) was not compara-
ble with the other low-flow oxygen groups; we presented the data
in Table 1; study authors reported no differences between oxygen
delivery devices (P = 0.99). As Frat 2015 included two compari-
son groups, we included data from both comparisons and halved
the data in the intervention group. Among the 1066 participants
(six studies) included in this analysis, we found no evidence of
less treatment failure with HFNC than with low-flow oxygen (risk
ratio (RR), Mantel-Haenszel (M-H), random-effects 0.79, 95%
confidence interval (CI) 0.49 to 1.27; P = 0.33; risk difference
(RD) -0.06, 95% CI - 0.15 to 0.03; P = 0.18; number needed
to treat for an additional beneficial outcome (NNTB) 16, 95%
CI 6 (NNTB) to 33 number needed to treat for an additional
harmful outcome (NNTH)). See Analysis 1.1. We used GRADE
to assess the quality of this evidence and considered a moderate
level of statistical heterogeneity in the pooled estimate (I2 = 58%);
some studies had high or unclear risk of bias, and there was some
indirectness in the effect estimate as pooled studies included some
participants that required oxygen therapy for respiratory failure
and others for post-extubation support. We therefore downgraded
the quality of this evidence by two levels to low.
2. In-hospital mortality
Four studies with 1585 participants reported mortality. Time
points were up to ICU discharge (Frat 2015; Maggiore 2014;
Stephan 2015) and up to day 28 of hospital admission (Parke
2013a). We did not combine Stephan 2015 in the meta-analy-
sis, as the comparison group (BiPAP) was not comparable with
the other low-flow oxygen groups; we presented the data in Table
1; study authors reported no differences between oxygen delivery
devices (P = 0.66). We included both comparison groups in Frat
2015 and halved data for the intervention group.When compared
with low-flow oxygen, HFNC provided no significant benefit in
terms of mortality (RR, M-H, random-effects 0.63, 95% CI 0.38
to 1.06; P = 0.08; RD -0.05, 95% CI -0.17 to 0.08; P value =
0.48; NNTB 1, 95% CI 1 (NNTB) to 12 (NNTH)).See Analysis
2.1. We downgraded the quality of this evidence by two levels to
low; some studies had unclear risk of bias, and the effect estimate
included participants requiring oxygen for different indications
(i.e. for respiratory failure and for post-extubation support).
3. Adverse events
Study authors reported the following adverse events: incidence of
nosocomial pneumonia (Frat 2015; Stephan 2015); visits to their
general practitioner (GP) for respiratory complications up to day
28 (Parke 2013a); episodes of oxygen desaturation (Parke 2011);
pneumothorax, and acute pseudo-obstruction (Stephan 2015);
and cardiac dysrhythmia, septic shock, and cardiorespiratory arrest
(Frat 2015). We could not combine data for nosocomial pneumo-
nia, as the comparison groups were different, and meta-analysis
was not possible because data were derived from single studies for
all other adverse events. Subsequently, we graded the certainty of
the evidence as low. Study authors reported no statistically signif-
icant differences between groups for each reported adverse event,
except Parke 2011, which reported fewer episodes of oxygen de-
saturation in the HFNC group (P = 0.009). Parke 2013a did not
provide P values for data; study authors reported the number of
participants who had seen their GP since discharge for respiratory
complications, and these data appeared comparable. We included
in Table 2 data for each adverse event as reported by study authors.
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Secondary outcomes
1. Duration in hours of any form of respiratory support
(mechanical ventilation, NIPPV, HFNC, standard oxygen)
Parke 2013a reported duration of respiratory support, and study
authors reported no differences in duration according to oxygen
delivery device (P = 0.13). We included in Table 3 data as reported
by study authors.
Stephan 2015 also reported duration of respiratory support. How-
ever, differences in method of use, with HFNC used continuously
and BiPAP used for approximately one hour at four-hourly inter-
vals, meant that inclusion of this information as outcome data was
not feasible.
2. Length of stay in days (ICU and hospital)
Five studies with 1743 participants (Corley 2014; Frat 2015;
Maggiore 2014; Parke 2013a; Stephan 2015) reported length of
stay (LOS) in the ICU. Stephan 2015 reported LOS as median
number of days; we included in Table 3 data as reported by study
authors which show no differences between groups (P = 0.77).
Frat 2015 reported LOS calculated at 90 days for both survivors
and non-survivors, and for both face mask and NIPPV groups. In
meta-analysis for Frat 2015, we included data for HFNC versus
standard oxygen therapy (face mask) for survivors. We found no
evidence of differences in LOS based on type of oxygen delivery
device (mean difference (MD), inverse variance (IV) 0.15 days,
95% CI -0.03 to 0.34; P = 0.10; 770 participants). See Analysis
3.1.We usedGRADE to assess the certainty of this evidence as low,
as analysis included studies with participants requiring respiratory
support for different indications, and some included studies had
unclear or high risk of bias.
Stephan 2015 reported hospital LOS as a median number of days;
we included in Table 3 data as reported by study authors, which
show no differences between groups (P = 0.59).
3. Respiratory effects
None of the included studies reported positive end-expiratory
pressure measured at the pharyngeal level nor work of breathing.
Degree of atelectasis on radiological examination
Corley 2014 reported atelectasis at days one and five, and Parke
2013a at days one and three. Both studies reported no differences
between groups on either day (Corley 2014 day 1, P = 0.70; day
5, P = 0.15; Parke 2013a day 1, P = 0.63; day 3, P = 0.69). See
Table 3.
Oxygenation
Included studies reported oxygenation data as PaO2/FiO2 ratio,
PaO2, and SpO2.
Five studies with 1340 participants reported PaO2/FiO2 within
the first 24 hours of treatment (Corley 2014; Frat 2015; Maggiore
2014; Parke 2011; Stephan 2015). We reported in Table 4 data
as reported by study authors for the BiPAP comparison (Stephan
2015). To avoid a unit of analysis issue, we included data from
Frat 2015 only for the standard oxygen therapy comparison
group.Meta-analysis demonstrated no differences between oxygen
delivery devices (MD, IV, random-effects 7.31, 95% CI -23.69
to 41.31; P = 0.67; 510 participants). See Analysis 4.1. We used
GRADE to downgrade the quality of this evidence to very low;
we were concerned about the substantial level of statistical het-
erogeneity evident in this estimate (I2 = 86%), as well as the very
wide confidence interval and differences among study participants
requiring respiratory support for different purposes.
Three studies with 355 participants reported PaO2 within the
first 24 hours of treatment (Frat 2015; Maggiore 2014; Parke
2011). We combined data, including results for the standard oxy-
gen therapy comparison only in Frat 2015. Results of meta-anal-
ysis showed no differences between HFNC and low-flow oxygen
therapies (MD, IV, random-effects 2.79, 95% CI -5.47 to 11.05;
P = 0.51). See Analysis 4.2.
Four studies with 512 participants reported SpO2 within the first
24 hours of treatment (Maggiore 2014; Parke 2011; Parke 2013a;
Rittayamai 2014), with no differences between oxygen delivery
devices (MD, IV, random-effects 0.72, 95% CI -0.73 to 2.17; P
= 0.33). See Analysis 4.3.
Two studies with 445 participants also reported SpO2 atmore than
24 hours of treatment (Maggiore 2014; Parke 2013a); although
favouring use of HFNC, this result did not show clinically impor-
tant differences in oxygen saturation according to oxygen delivery
device (MD, IV, random-effects 1.28, 95% CI 0.02 to 2.55; P =
0.05). See Analysis 4.4.
Maggiore 2014 provided single study data for other longer-term
oxygenation effects (PaO2/FiO2 and PaO2). Study authors re-
ported PaO2/FiO2 at 36 hours and 48 hours, both with a higher
ratio in the HFNC group (P = 0.0003 and P = 0.01, respectively),
as well as higher values for PaO2 in the HFNC group (P = 0.04).
See Table 3.
Carbon dioxide clearance
Four studies (Frat 2015; Parke 2011; Parke 2013a; Stephan 2015)
reported carbon dioxide clearance (PaCO2). We included data
for the BiPAP comparison group (Stephan 2015) in Table 4. We
included data from the standard oxygen therapy comparison in
Frat 2015. Pooled data analysis revealed no differences in carbon
dioxide clearance between groups (MD IV, random-effects -0.75,
95% CI -2.04 to -0.55; 590 participants). See Analysis 5.1.
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Respiratory rate
Nine studies (Chanques 2013; Corley 2014; Frat 2015; Lemiale
2015,Maggiore 2014; Parke 2011; Parke 2013a; Rittayamai 2014;
Stephan 2015), which included 1646 participants, reported short-
term changes in respiratory rate up to 24 hours after commence-
ment of treatment. We did not include study data for Lemiale
2015, which reported data as median values; we included in Table
3 data as reported by study authors. Meta-analysis of the six stud-
ies comparing low-flow oxygen (with data for the standard oxy-
gen therapy comparison group in Frat 2015) (Corley 2014; Frat
2015;Maggiore 2014; Parke 2011; Parke 2013a; Rittayamai 2014)
demonstrated no differences in respiratory rates between groups
(MD, IV, random-effects -1.51, 95% CI -3.36 to 0.35; P = 0.11;
867 participants). See Analysis 6.1. Meta-analysis of the two stud-
ies comparing CPAP and BiPAP (Chanques 2013; Stephan 2015)
revealed a difference, with an improved respiratory rate in the
HFNC group, but this was not clinically important (MD, IV, ran-
dom-effects -0.89, 95% CI -1.74 to -0.05; 834 participants).
Two studies (Maggiore 2014; Parke 2013a) examined longer-term
changes in respiratory rate among 445 participants, with no differ-
ences between oxygen delivery devices (MD, IV, random-effects -
2.71, 95% CI -7.12 to 1.70; P = 0.23). See Analysis 6.2.
4. Patient-reported outcomes
Dyspnoea
Six studies with 1431 participants reported patient dyspnoea
(Corley 2014; Frat 2015; Lemiale 2015; Rittayamai 2014;
Schwabbauer 2014; Stephan 2015).We could not perform ameta-
analysis for this outcome, as studies had used different scales in
reporting results.
Corley 2014 used a modified Borg scale (0 = no dyspnoea, 10 =
maximal dyspnoea) and reported results for one hour and eight
hours after intervention. Results at eight hours were statistically
significant (P = 0.008), but study authors reported that this was
not a clinically important difference. Frat 2015 used five categories
for dyspnoea results (marked improvement, slight improvement,
no change, slight deterioration, marked deterioration). Study au-
thors reported improvement in the HFNC group, in which 19%
of participants reported a marked improvement and 46% reported
a slight improvement. In the standard oxygen group, percentages
were 5% and 26%, respectively, and in the noninvasive ventilation
group, percentages were 13% and 40%, respectively (P < 0.001).
Among 17 participants, Rittayamai 2014 measured dyspnoea on
a 0 to 10 scale, on which 0 = no dyspnoea and 10 = maximal
dyspnoea. Study authors reported a higher dyspnoea score in the
low-flow oxygen group (P = 0.04). Stephan 2015 used three cate-
gories for dyspnoea results (improvement, no improvement, and
deterioration). Study authors reported no statistically significant
differences between groups for each category. In theHFNC group,
58.6% of participants reported an improvement, 37.5% reported
no improvement, and 4% reported deterioration; in the BiPAP
group, percentages were 65.8%, 29.7%, and 4.5%, respectively.
Lemiale 2015 used a scale of 0 to 10 (0 = absence of dyspnoea,
10 = worst possible dyspnoea) with no statistically significant dif-
ferences between groups (median 3 (interquartile range 2 to 6)
HFNC group; median 3 (interquartile range 5 to 9) low-flow
group; P = 0.40).
We were unable to report data for Schwabbauer 2014, as study
authors had not provided data from the first cross-over period.
Comfort
Seven studies with 1717 participants (Chanques 2013; Frat 2015;
Lemiale 2015; Maggiore 2014; Parke 2013a; Rittayamai 2014;
Stephan 2015) compared comfort or discomfort over the short
term between HFNC and low-flow oxygen. Maggiore 2014 asked
participants to rate their discomfort on a scale of 0 to 10, with
0 = no discomfort and 10 = maximal discomfort. Rittayamai
2014used a comfort scale on which 0 = maximal comfort and 10 =
minimum comfort. Parke 2013a used a comfort scale on which 0 =
no comfort and 10 = maximal comfort. Although the terminology
of the scales differed between the three studies (Maggiore 2014;
Parke 2013a; Rittayamai 2014), we were able to pool study data,
as participants in Maggiore 2014 and Rittayamai 2014 essentially
rated comfort on the same scale, and inverting mean scores for
the data from Parke 2013a resulted in data on a comparable scale
withMaggiore 2014 andRittayamai 2014. In studies that reported
different time points for measures of comfort, we selected the
earliest time points (Maggiore 2014 at one hour; Parke 2013a
at four hours; Rittayamai 2014 at 30 minutes). Meta-analysis of
these three studies showed no differences in participants’ level of
comfort according to oxygen delivery device (MD, IV, random-
effects 0.14, 95%CI -0.65 to 0.93; 462 participants). See Analysis
8.1. We used GRADE to assess the quality of this evidence as low,
as analysis included studies with participants requiring respiratory
support for different purposes, and some included studies had
unclear or high risk of bias. We downgraded the quality of this
evidence to moderate owing to heterogeneity and unclear risk of
bias in two of the included studies; therefore, confidence in the
effect estimates may change with further research.
Lemiale 2015 used a scale of 0 to 10 (0 = absence of discomfort,
10 = worst possible discomfort) with no statistically significant
differences between groups measured at 120 minutes (P = 0.88).
In Stephan 2015, participants rated their comfort on a five-point
scale, whichwas categorised as ’poor’, ’acceptable’, or ’good’. Study
authors reported no statistically significant differences between
groups at one hour (P = 0.32). We included in Table 3 data as
reported by study authors.
Two studies (Maggiore 2014; Parke 2013a) reported longer-term
measures of patient comfort (i.e. after 24 hours), which demon-
strated no improvement in comfort whenHFNCwere used (MD,
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IV, random-effects -0.36, 95%CI -3.70 to 2.98; 445 participants).
See Analysis 8.2. We downgraded the quality of this evidence to
very low; therewere only two studieswith unclear risk of bias across
some domains and a substantial level of statistical heterogeneity
(I2 = 97%), which we were unable to explain through subgroup
analysis.
Mouth dryness
Maggiore 2014 reported data on subjective mouth dryness, with
more participants in the low-flowoxygen group than in theHFNC
group reporting mouth dryness (P = 0.016). We included in Table
3 data as reported by study authors.
Cuquemelle 2012 included mouth dryness as one a study out-
come, but we were unable to obtain data from study authors for
this outcome. Study authors reported no significant differences
between groups in relation to mouth dryness.
Patient refusal to continue with treatment
Parke 2013a reported participants who were unable to continue
with treatment owing to discomfort or excessive heat. Study au-
thors reported 20 participants in the HFNC group and no partic-
ipants in the low-flow oxygen group who were unable to continue
with treatment. We also reported data in Table 2.
5. Cost comparison of treatment
None of the included studies reported this outcome.
Subgroup analysis
We performed subgroup analysis on our primary analysis for stud-
ies that included participants requiring oxygen therapy for respi-
ratory failure and studies that included participants requiring oxy-
gen therapy following extubation. Analysis showed no differences
in treatment failure based on the reason for oxygen therapy (Chi²
= 0.01, df = 1; P = 0.94; I2 = 0%) and no differences in failure rates
in both groups (respiratory failure: RR,MH, random-effects 0.79,
95% CI 0.56 to 1.11; and post extubation: RR, MH, random-
effects 0.84; 95% CI 0.17 to 4.21). See Analysis 9.1.
Sensitivity analysis
Risk of bias
Among the studies included in our primary analyses of treatment
failure and mortality (Analysis 1.1 and Analysis 2.1), we judged
Frat 2015, Parke 2011, and Parke 2013a to have high risk of bias.
We removed these studies from analyses and noted no changes
in the significance of findings. Other studies that we judged to
have unclear risk of selection bias had not reported data for these
outcomes.
Effects model
We had selected a random-effects model for analysis of each out-
come, as included studies were few. We re-calculated our primary
analysis using a fixed-effect model. This altered the result to a
statistically significant effect, with fewer treatment failures when
HFNC was used (RR, MH, fixed-effect 0.77, 95% CI 0.60 to
0.98). However, data with a fixed-effect model should be inter-
preted cautiously, as there remain unexplained moderate levels of
statistically heterogeneity (I2 = 58%) and differences between in-
cluded participants that would support use and interpretation of
a random-effects model for this outcome.
D I S C U S S I O N
Summary of main results
We identified eight randomized controlled trials (Corley 2014;
Cuquemelle 2012; Frat 2015; Lemiale 2015; Maggiore 2014;
Parke 2011; Parke 2013a; Stephan 2015) and three randomized
cross-over trials (Chanques 2013; Rittayamai 2014; Schwabbauer
2014) comparing high-flow nasal cannulae (HFNC) with low-
flow oxygen in participants admitted to the intensive care unit
(ICU). Data comparing HFNC with continuous positive airway
pressure (CPAP) and bilevel positive airway pressure (BiPAP) were
very limited and were provided only in two studies (Chanques
2013 and Stephan 2015, respectively). These eight studies in-
cluded a total of 1972 adult participants.
For primary outcomes of failure of treatment, mortality, and ad-
verse events, low-quality evidence showed that no differences be-
tween HFNC and low-flow oxygen were evident. ICU length of
stay did not differ between HFNC and low-flow oxygen groups,
nor did the duration of any form of respiratory support. Atelectasis
did not differ between HFNC and low-flow oxygen in two stud-
ies. Oxygenation, carbon dioxide clearance, and respiratory rate
data were analysed as short-term effects (i.e. up to 24 hours after
initiation of therapy) and as long-term effects (i.e. longer than 24
hours after initiation of therapy). Analysis showed no differences
in oxygenation and carbon dioxide clearance between HFNC and
low-flow oxygen over the short term; only two studies provided
evidence that HFNC improved oxygenation saturation after 24
hours of use, but these differences were small and were not clin-
ically important. Analysis showed no significant differences be-
tween HFNC and low-flow oxygen in short- or long-term effects
on respiratory rate. In the only comparison in the review with
CPAP and BiPAP; the difference in short-term effects of these
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therapies on respiratory rate was small and was not clinically im-
portant, nor could it be interpreted with any certainty owing to
the very small sample size.
In terms of patient-reported outcomes, six studies had reported
dyspnoea but on scales that were not compatible and could not be
combined. Authors of three studies reported statistically significant
improvement in dyspnoea for participants using HFNC. Patient
comfort data were analysed and showed no differences between
HFNC and low-flow oxygen. One study provided data for short-
term and long-term patient-reported mouth dryness, which was
significantly less with HFNC than with low-flow oxygen. One
study reported that participants randomized to low-flow oxygen
were more likely than those randomized to HFNC to continue
with their treatment owing to reports of discomfort caused by
excessive heat.
Study authors reported no data for positive end-expiratory pres-
sure measured at the pharyngeal level; work of breathing; or cost
comparison of treatment.
Overall completeness and applicability of
evidence
We identified 11 trials of HFNC in adult participants in the ICU.
Six trials included participants who required oxygen therapy for
respiratory failure, and five included participants who required
oxygen therapy post extubation.Data for this reviewwere therefore
applicable to these two indications. Studies included data on most
outcomes of interest for this review, although studies addressing
each outcome were often few, or did not report data comparably
and could not be combined in a meta-analysis. This also limited
the potential for subgroup analyses, which could have explored
heterogeneity between studies.
Quality of the evidence
The included studies enrolled small numbers of participants; four
studies each included no more than 30 participants. Whether they
were adequately powered to detect differences between groups
was uncertain, especially the smaller studies. Indeed, two studies
(Cuquemelle 2012; Parke 2011) stated that they were not suffi-
ciently powered to detect differences between groups for the pri-
mary review outcome of failure of treatment. We used GRADE to
assess the quality of the evidence for seven of our outcomes. Not
all studies had adequately described methods of randomization or
allocation concealment, and blinding of outcome assessment was
inconsistent between studies. Differences between study partici-
pants in indications for oxygen therapy may have influenced the
results as well. Few studies were available for each of our outcomes.
We were not able to explain substantial levels of statistical hetero-
geneity for some results. We considered each of these factors and
graded evidence of most outcomes as low or very low quality.
This GRADE assessment meant that we were not certain of the
effect estimates that we had presented for each outcome.
Potential biases in the review process
Through adhering to the processes set out in the review protocol,
the review authors believe that the review was conducted in a way
that minimized bias in the review process. Review methods used
were set a priori, which is a robust way of ensuring transparency
and reproducibility. Study selection, data extraction, and risk of
bias assessment were conducted independently by two review au-
thors, who achieved complete agreementwithout contention. Two
review authors (AC and JF) have declared potential conflicts of in-
terest due to a prior relationship with manufacturers of theHFNC
system (see Declarations of interest) but believe that these rela-
tionships did not affect their ability to impartially conduct this
review.
We identified two studies for which we were able to obtain only
abstracts. We reran the search in December 2016 and identified
four studies of potential interest. This review did not include data
from these studies, and we will incorporate these data during the
formal review update.
Agreements and disagreements with other
studies or reviews
Most of the evidence around HFNC use is derived from observa-
tional studies, and this is the first systematic review andmeta-anal-
ysis that limits included studies to randomized or quasi-random-
ized controlled trials. Kernick 2010 performed the first systematic
review of the literature on adult participants, which included eight
studies, but the review authors were unable to perform a meta-
analysis owing to the paucity of data. Nevertheless, review authors
found preliminary evidence to support the use of HFNC for im-
proving oxygenation among adults in intensive care.
Since that time, several comprehensive literature reviews (El-
Khatib 2012; Gotera 2013; Lee 2013; Ricard 2012; Scala 2014;
Ward 2013) have examined available evidence. These concluded
that HFNC has a place in providing respiratory support for pa-
tients with hypoxic respiratory failure by improving short-term
respiratory parameters such as oxygenation, respiratory rate, and
positive airway pressure. These review authors noted some support
for HFNC use among patients with hypoxic respiratory failure
but concluded that its role in providing respiratory support for
patients with other aetiologies has yet to be determined. Through
our review, we were not able to establish any certainties about
HFNC use, particularly for those who require respiratory support
for respiratory failure or post extubation.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
We found insufficient evidence to determine effects of HFNC in
the delivery of respiratory support to adult intensive care patients.
In addition, the included trials have some potentially problematic
limitations, particularly in the area of lack of blinding of outcome
assessors or limited detail on study methods for adequate assess-
ment of bias.
Implications for research
The small number of studies included in this review highlights
the need for further research. This is an emerging field of inter-
est, and larger-scale randomized controlled trials conducted to ad-
dress clinically important outcomes are currently under way (see
Characteristics of ongoing studies). Further research should help
to clarify the level of safety and efficacy of HFNC in providing
respiratory support for adult ICU patients.
Upcoming trials must be of sufficient size and must be method-
ologically rigorous; they should place particular emphasis on de-
termining the role of HFNC in respiratory failure of different aeti-
ologies and on comparing use of HFNC versus other forms of res-
piratory support such as non-invasive ventilation, while focusing
more on clinically important long-term outcome measures such
as impact on invasive and non-invasive ventilation rates and mor-
tality, rather than on surrogate outcomes. Trials should examine
rates and severities of adverse events associated with HFNC use.
In addition, the introduction of new therapies requires effective
economic evaluations to determine their economic cost or bene-
fit. As no current evidence confirms detriment or harm associated
with HFNC, continued investigation appears warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chanques 2013
Methods Randomized cross-over study, single-centre study
Participants Total number of participants = 10
Setting: medical-surgical ICU; Montpelier, France
Inclusion criteria: ≥ 18 years old hospitalized in a medical-surgical ICU, planned for
tracheostomy tube removal which was placed in the ICU for weaning from mechanical
ventilation
Exclusion criteria: pregnancy, adult under tutelage, contraindications for NIV
Baseline characteristics (all patients)
Age: 54 to 66 years
Respiratory rate (breaths/min) median (25th-75th percentiles): 18 (22 to 20)
PaCO2: not reported
PaO2/FiO2: not reported
Interventions 1. High-flow face mask with a reservoir bag
2. Optiflow high-flow nasal cannulae
3. Boussignac oxygen therapy system
Flow rates of 15, 30, and 45 litres per minute were tested in a randomized order for each
device. For each device and flow rate, participants were asked to have their mouth open
and mouth closed in a randomized order. Each device was used for 5 minutes, with 15-
minute washout between treatments
Outcomes Tracheal pressure, FiO2 delivered, respiratory discomfort, respiratory rate (at end of each
treatment period), noise intensity
Notes Funding sources/declarations of interest: Study authors disclose funding of EURO3000
fromFisher &PaykelHealthcare, France, whichwas used to acquire technical equipment
and clinical research insurance, and to present results at scientific meetings
Study dates: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomization not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants and personnel
to treatment allocation
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Chanques 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants were outcome assessors for res-
piratory and auditory discomfort on a stan-
dardized scale. Investigators were outcome
assessors for other outcomes, but standard-
ized tools were used for measurement, re-
ducing risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk One participant was excluded owing toma-
jor intolerance to the device but possibly
should have been regarded as a treatment
failure. In such a small study, this is likely
to have had an effect
Owing to inability of 4 participants in the
Boussignac group to adhere to the protocol,
it is likely that data are incomplete; however
it is not mentioned how this was handled
in the analysis
Selective reporting (reporting bias) Unclear risk ISRCTN15995925. Retrospectively regis-
tered in August 2012. Not possible to es-
tablish any reporting bias through compar-
ison with the trial register protocol
Other bias Unclear risk Fifteen-minute washout between devices
but no mention of respiratory support re-
ceived by the participant during this pe-
riod. No washout period between changes
in flow rate, so carry-over effect may skew
data
Funding from manufacturer: paper does
not state whether manufacturer was in-
volved in study design or management
Corley 2014
Methods Randomized controlled trial, single-centre study
Participants Total number of participants = 155
Setting: ICU; Brisbane, Australia
Inclusion criteria: ≥ 18 years, BMI ≥ 30 kg/m2, scheduled to undergo cardiac surgery
on cardiopulmonary bypass
Exclusion criteria: ventilation time > 36 hours, extubation onto NIPPV, requirement for
tracheostomy, extubation as part of end-of-life treatment
Baseline characteristics
1. HFNC
Age mean (SD): 63 (± 11.4) years
Respiratory rate (breaths/min): not reported
PaCO2: not reported
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Corley 2014 (Continued)
PaO2/FiO2: not reported
2. Standard oxygen therapy
Age mean (SD): 65 (± 11.1) years
Respiratory rate (breaths/min): not reported
PaCO2: not reported
PaO2/FiO2: not reported
Interventions 1. HFNC (Optiflow; Fisher & Paykel Healthcare); n = 81
Humidifed to 37°C, flow rate commenced at 35 L/min, then titrated to a maximum of
50 L/min; FiO2 titrated to maintain SpO2 ≥ 95% for 8 hours, with short breaks for
nasal care or mobilisation
2. Standard oxygen therapy; n = 74
Oxygen delivered at 2 to 4 L/min via nasal cannulae or 6 L/min via simple face mask
titrated to maintain SpO2 ≥ 95%
Both applied after extubation
Outcomes Atelectasis on chest X-ray, oxygenation, respiratory rate, subjective dyspnoea, failure of
allocated treatment
Notes Funding/declarations of interest: unrestricted grant from Fisher & Paykel Healthcare;
two study authors received travel and accommodation support from Fisher & Paykel
Healthcare; manufacturer had no part in study design, data collection, data analysis, or
creation of the manuscript
Study dates: February 2011 to March 2012
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random numbers table in
blocks of 8
Allocation concealment (selection bias) Low risk Use of numbered, opaque envelopes to
maintain allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants and personnel
but unlikely to influence performance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Primary outcome assessment (atelectasis)
blinded, but other outcome assessment not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Low risk ACTRN12610000942055. Prospective
trial registration. All outcomes reported as
stated in trial registry
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Corley 2014 (Continued)
Other bias Low risk Baseline characteristics largely comparable.
Funding provided by manufacturer, who
was not involved in study design and man-
agement
Cuquemelle 2012
Methods Parallel randomized controlled trial (for 24 hours) with a final cross-over period (for 4
hours); single-centre study
Participants Total number of participants = 30
Setting: medical ICU; Paris, France
Inclusion criteria: acute hypoxaemic respiratory failure requiring at least 4 L/min oxygen
to maintain SpO2 above 95%
Exclusion criteria: use of NIV or invasive mechanical ventilation; presence of delirium
that impaired the ability of the participant to rate dryness; preference for 1 of the 2
oxygen delivery systems
Baseline characteristics
Age: 39 to 77 years
Respiratory rate (breaths/min): not reported
PaCO2: not reported
PaO2/FiO2: not reported
Interventions 1. HFNC
Optiflow; Fisher & Paykel Healthcare; humidified to 37°C, flow rate at 40 L/min
2. Standard oxygen therapy
Use of a flow meter from wall oxygen without humidification
Randomized to receive therapy during first 24 hours, then crossed-over to alternative
therapy for 4 hours to reduce drop-outs
Outcomes Nasal airway calibre was measured by acoustic rhinometry at baseline, after 4 and 24
hours, and 4 hours after cross-over. Dryness of the nose, mouth, and throat was auto-
evaluated and was assessed blindly by an otorhinolaryngologist. After cross-over, partic-
ipants were asked which system they preferred
Notes Funding/declarations of interest: relationship with Fisher & Paykel Healthcare disclosed,
but manufacturers had no part in the study
Study dates: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated in the paper
Allocation concealment (selection bias) Unclear risk Not stated in the paper
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Cuquemelle 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants to treatment
allocation but unlikely to affect outcome.
No mention of blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants were outcome assessors for
dryness scores - unblinded but unlikely to
affect the result
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 37 participants randomized, 7 were ex-
cluded from analysis, as they were unable
to complete the study (5 owing to deterio-
ration and 2 because of rapid improvement
in respiratory status)
Selective reporting (reporting bias) Unclear risk Trial registration not reported in the paper.
Unable to establish whether outcomes were
reported according to prepublished proto-
col or trial registration documents
Other bias High risk Although they did not reach statistical sig-
nificance, potentially clinically important
differences in baseline characteristics were
noted. Specifically, participants in the in-
tervention groupwere older and had higher
rates of infectious pneumonia. Reasons for
exclusion potentially related to treatment
Frat 2015
Methods Randomized controlled trial, multi-centre
23 ICUs
Participants Total number of participants = 313
Setting: ICUs; France and Belgium
Inclusion criteria: consecutive patients, aged≥ 18 years, respiratory rate > 25 breaths per
minute, PaO2/FiO2 ≤ 300 mmHg while patient was breathing oxygen at flow rate ≥
10 L/min for at least 15 minutes, PaCO2 not higher than 45 mmHg, absence of clinical
history of underlying chronic respiratory failure
Exclusion criteria: PaCO2 > 45 mmHg, exacerbation of asthma or chronic respiratory
failure, cardiogenic pulmonary oedema, severe neutropenia, haemodynamic instability,
use of vasopressors, GCS ≤ 12, contraindications to NIV, urgent need for tracheal
intubation, a do-not-resuscitate order, or decision to not participate
Baseline characteristics
1. HFNC
Age mean (SD): 61 (± 16) years
Respiratory rate (breaths/min) mean (SD): 33 (± 6)
PaCO2 (mmHg) mean (SD): 36 (± 6)
PaO2/FiO2(mmHg) mean (SD): 157 (± 89)
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2. Standard oxygen
Age mean (SD): 59 (± 17) years
Respiratory rate (breaths/min) mean (SD): 32 (± 6)
PaCO2 (mmHg) mean (SD): 35 (± 5)
PaO2/FiO2 (mmHg) mean (SD): 161 (± 73)
3. Non-invasive ventilation
Age mean (SD): 61 (± 17) years
Respiratory rate (breaths/min) mean (SD): 33 (± 7)
PaCO2 (mmHg) mean (SD): 34 (± 6)
PaO2/FiO2 (mmHg) mean (SD): 149 (± 72)
Interventions 1. HFNC; n = 106
Oxygenpassed through heated humidifier, applied continuously through large-bore nasal
prongs; gas flow rate 50 L/min, FiO2 1.0 at initiation (Optiflow); adjusted to maintain
SpO2 ≥ 92%; for at least 2 calendar days, then this could be stopped or participant
switched to standard oxygen therapy
2. Standard-oxygen; n = 94
Continously through nonrebreather face mask; flow rate ≥ 10L/min; adjusted to main-
tain SpO2 ≥ 92%; until participant recovered or was intubated
3. Non-invasive ventilation; n = 110
Through a face mask connected to an ICU ventilator with pressure support applied in
NIV mode; adjusted to obtain expired tidal volume of 7 to 10 mL/kg of predicted body
weight, with initial PEEP between 2 and 10 cm of water; adjusted to maintain SpO2 ≥
92%; minimum of 8 hours per day for at least 2 calendar days; applied during sessions
of at least 1 hour, could be resumed if respiratory rate > 25 breaths per minute or SpO2
less than 92%; between noninvasive-ventilation sessions, participants received high-flow
oxygen
Outcomes Participants requiring endotracheal intubation within 28 days of randomization, mor-
tality in ICU, mortality at 90 days, number of ventilator-free days between day 1 and
day 28, duration of ICU stay, complications during ICU stay, dyspnoea, comfort
Notes Funding/declarations of interest: equipment provided by Fisher & Paykel Healthcare,
but manufacturer had no involvement in the study
Study dates: February 2011 to April 2013
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of centralizedWeb-based management
system, blocks of 6, stratified by centre
and history or no history of cardiac insuf-
ficiency
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Lack of blinding unlikely to affect perfor-
mance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 losses (2 in standard oxygen group and 1
in NIV group) due to withdrawal of con-
sent. Small number of losses unlikely to in-
fluence outcome data
Selective reporting (reporting bias) Low risk NCT01320384. Study prospectively regis-
tered. Outcomes reported as stated in pro-
tocol with some data reported in supple-
mentary index
Other bias High risk Participants in NIV monitoring group
given HFNC between ventilation sessions
Unequal numbers of participants in each
group, not explained, but baseline charac-
teristics comparable
Equipment provided by manufacturer, but
no involvement in study design and man-
agement
Lemiale 2015
Methods Randomized controlled trial, multi-centre
4 ICUs
Participants Total number of participants = 102
Setting: ICUs; France
Inclusion criteria: consecutive immunocompromised patients admitted to ICU for acute
respiratory failure, aged > 18 years
Exclusion criteria: hypercapnia (> 45 mmHg), mechanical ventilation before ICU ad-
mission, need for immediate NIV or invasive mechanical ventilation, and patient refusal
to participate in study
Baseline characteristics
1. HFNC:
Age median (25th to 75th percentile): 59.3 (43 to 70) years
Respiratory rate (breaths/min) median (25th to 75th percentile): 26 (21.7 to 31.2)
PaCO2: not reported
PaO2/FiO2 mmHg: median (25th to 75th percentile): 128 (48 to 178)
2. Venturi mask
Age median (25th to 75th percentile): 64.5 (53.25 to 72) years
Respiratory rate (breaths/min) median (25th to 75th percentile): 27 (22 to 32.2)
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PaCO2: not reported
PaO2/FiO2 mmHg median (25th to 75th percentile): 100 (40 to 156)
Interventions Participants were randomly allocated to oxygen therapy groups for a 2-hour period
1. HFNC; n = 52
Heated, humidified circuit, with initial flow of 40 to 50 L/min; FiO2 100%, which was
then adjusted to maintain SpO2 ≥ 95%
2. Venturi mask; n = 48
FiO2 initially 60%, 15 L/min, then adjusted to maintain SpO2 ≥ 95%
Outcomes Need for invasive mechanical ventilation or NIV during or at the end of the 2-hour study
period; VAS scores for comfort, thirst, and dyspnoea (all at 120 minutes); respiratory
rate (at 120 minutes); heart rate
Notes Funding/declarations of interest: Fisher & Paykel Healthcare provided oxygen delivery
devices and funds for study insurance and presentation of results. The sponsors had no
role in designing or conducting the study
Study dates: November 2012 to April 2014
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients described as randomly allocated,
with stratification on study centre by per-
muted block method
Allocation concealment (selection bias) Low risk Use of opaque, sealed envelopes to ensure
identity concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Lack of blinding unlikely to influence per-
formance for review outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss of two participants after randomiza-
tion due to withdrawal of consent. Low
number, unlikely to influence results
Selective reporting (reporting bias) Unclear risk NCT02424773. Retrospective registration
in April 2015. Therefore not feasible to
judge if any reporting bias. All outcomes
reported from methods section
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Other bias Low risk Some funding supplied by manufacturer
but no involvement in study design orman-
agement
Some differences in baseline characteristics
but not clinically significant
Maggiore 2014
Methods Randomized controlled trial, multi-centre study
2 ICUs
Participants Total number of participants = 105
Setting: ICUs; Rome and Novara, Italy
Inclusion criteria: patients who were mechanically ventilated for longer than 24 hours,
passed a spontaneous breathing trial, PaO2/FiO2 ratio < 300 at the end of the trial
Exclusion criteria: tracheostomy, age < 18 years, pregnancy, anticipated need for non-
invasive ventilation after extubation
Baseline characteristics
1. HFNC
Age mean (SD): 65 (± 18) years
Respiratory rate (breaths/min) mean (SD): 23 (± 5)
PaCO2 mmHg mean (SD): 34.7 (± 7.6)
PaO2/FiO2mmHg mean (SD): 239.4 (± 42.4)
2. Venturi mask
Age mean (SD): 64 (± 17) years
Respiratory rate (breaths/min) mean (SD): 23 (6)
PaCO2 mmHg mean (SD): 36 (± 7.1)
PaO2/FiO2 mmHg mean (SD): 241.7 (± 51.1)
Interventions 1. HFNC; n = 53
50 L/min
2. Venturi mask; n = 52
Both used after extubation. FiO2 was set to obtain SpO2 92% to 98% (88% to 95% in
chronic obstructive pulmonary disease). Applied for 48 hours or until ICU discharge
Outcomes Arterial blood gas, SaO2, FiO2, PaO2/FiO2 ratio, respiratory rate, mean arterial pressure,
heart rate, and discomfort (recorded at 1, 3, 6, 12, 24, 36, and 48 hours). Adverse events
(displacement of oxygenation device, oxygen desaturation post extubation requiringNIV
or endotracheal intubation). Length of stay and mortality
Notes Funding/declarations of interest: supported by an unrestricted research grant from Fisher
& Paykel Healthcare and by an independent research grant
Study dates: November 2010 to April 2011
3 secondary references to this study (conference reports)
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A unique random number sequence that
was computer generated
Allocation concealment (selection bias) Unclear risk Participants were randomly assigned, us-
ing a block size of 30, to Optiflow or
Venturi mask in a blinded fashion with
opaque envelopes - no specific mention as
to whether the envelopes were consecu-
tively numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and personnel not
possible but unlikely to affect outcome
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Database monitored by independent third
parties, analysis performed as agreed before
commencement of the study
However, assumed that outcome assessors
were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Low risk NCT01575353. Retrospectively registered
in December 2010 (but only shortly be-
fore start of recruitment). All outcomes re-
ported as stated in protocol. Length of stay
and mortality rates reported but not previ-
ously stated in protocol
Other bias Unclear risk Multiple interim analyses performed (3 ab-
stracts presented from same study)
Unrestricted grant from manufacturer.
Does not state whether manufacturer was
involved in study design and management
Parke 2011
Methods Randomized controlled trial, single-centre study
Participants Total number of participants = 56
Setting: cardiothoracic and vascular ICU; Auckland, New Zealand
Inclusion criteria: Patients in a cardiothoracic and vascular ICU with mild to moderate
hypoxaemic respiratory failure defined by study authors as follows: receiving ≥ 4 L/
min of oxygen via nasal cannula for longer than 4 hours and/or respiratory rate ≥ 25
breaths per minute and/or increased work of breathing, evidenced by clinical signs such
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as dyspnoea, in-drawing, accessory muscle use, and diaphoresis; or receiving ≥ 6 L/min
of oxygen via face mask for longer than 2 hours, or respiratory rate ≥ 25 breaths per
minute, or both, or increased work of breathing, as evidenced by clinical signs such as
dyspnoea, in-drawing, accessory-muscle use, and diaphoresis, or both
Exclusion criteria: patients requiring imminent mechanical ventilation and those under
orders to not receive mechanical ventilation
Baseline characteristics
1. HFNC
Age mean (range): 64 (39 to 83) years
Respiratory rate (breaths/min) mean (SD): 21 (± 7)
PaCO2 mmHg mean (SD): 43 (± 7)
PaO2/FiO2: not reported
2. Standard oxygen therapy
Age mean (range): 64 (26 to 85) years
Respiratory rate (breaths/min) mean (SD): 18 (± 8)
PaCO2 mmHg mean (SD): 42 (± 7)
PaO2/FiO2: not reported
Interventions 1. HFNC; n = 29
Optiflow, Fisher & Paykel Healthcare, with MR880 humidifier, RT241 heated delivery
tube, and RT033 large/RT034 small, wide-bore nasal cannula; therapy commenced at
an initial flow of 35 L/min; flow and FiO2 titrated to SpO2 or SaO2 of 95%. Duration
of oxygen therapy not reported
2. Standard oxygen therapy; n = 27
HFFM (standard face mask, MR850 humidifier, RT308 heated delivery tube and air
entrainer, Fisher&PaykelHealthcare) with an aerosol mask (HudsonRCI, TFXMedical,
High Wycombe, UK); flow rate ≤ 15 L/min; humidified oxygen delivered at 31°C and
32 mg H2O/L; titrated to an SpO2 or SaO2 95%. Duration of oxygen therapy not
reported
Outcomes Assessment score, arterial blood gas values, SpO2, respiratory rate, and heart rate at base-
line, 30 minutes, 1 hour, 2 hours, and 4 hours after randomization, then as per unit
protocol. Continuous SpO2 data and instances of desaturation (SpO2 93% for longer
than 5 seconds) were collected. Episodes were discounted if the SpO2 trace indicated
signal interference or signal loss. Allocated therapy was considered successful if partici-
pants were maintained on or were weaned from their assigned oxygen therapy within 24
hours of enrolment. Failure of therapy was defined as worsening respiratory failure that
required a change in the respiratory support device within 24 hours of study enrolment
Notes Funding/declarations of interest: Fisher & Paykel Healthcare consulted regarding study
design and data analysis, and paid for statistical analysis
Study dates: not reported
Note: some additional outcome data retrieved through email contact with study authors
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Opaque sealed envelopes but no mention
of whether numbered or not
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants or personnel
to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not men-
tioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of 60 enrolled in the study, 4 participants
(1 from the HFNC group, and 3 from the
HFFM group) were excluded: 2 refused
consent for all data collection, and 2 failed
the screening. Five of 27 participants in the
high-flow facemask groupwere switched to
nasal high flow - no mention of how these
data were treated
Selective reporting (reporting bias) High risk ACTRN012606000139572. Prospective
registration in April 2006. Reported addi-
tional outcomes that were not stated in trial
registration records (outcomes in protocol
were arterial blood gas, heart rate, blood
pressure, and respiratory rate)
Other bias High risk Underpowered for outcome of failure of
treatment. Risk of bias introduced with in-
volvement of manufacturer in study design
and analysis
Parke 2013a
Methods Randomized controlled trial, single-centre study
Participants Total number of participants = 340
Setting: ICU; Auckland, New Zealand
Inclusion criteria: All patients undergoing elective cardiac surgery utilizing cardiopul-
monary bypass were eligible for inclusion in this study if aged≥ 18 years and undergoing
surgery involving full median sternotomy
Exclusion criteria: contraindication to HFNC, e.g. presence of a nasal septal defect, and
previous recruitment
Baseline characteristics
1. HFNC
39High-flow nasal cannulae for respiratory support in adult intensive care patients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Parke 2013a (Continued)
Age median (range): 65 (19 to 88) years
Respiratory rate (breaths/min) mean (SD): 16.6 (± 1.9)
PaCO2: not reported
PaO2/FiO2: not reported
2. Simple face mask
Age median (range): 66 (21 - 87) years
Respiratory rate (breaths/min) mean (SD): 16.5 (± 1.7)
PaCO2: not reported
PaO2/FiO2: not reported
Interventions 1. HFNC; n = 169
Optiflow system; flow rate 45 L/min
2. Simple face mask; n = 171
Oxygen at 2 to 4 L/min via simple face mask or nasal prongs; FiO2 in both groups was
titrated to maintain SpO2 > 93%
Oxygen therapy started after extubation. Duration of therapy not reported
Outcomes Primary outcome: number of participants with SpO2/FiO2 ratio ≥ 445 on day 3 after
cardiac surgery
Secondary outcomes: atelectasis score of chest X-rays, spirometry, re-admission to ICU
for respiratory causes, ICU and hospital length of stay, mortality, incidence of respiratory
complications on day 28, respiratory rate, oxygenation, use of adjunctive respiratory
support therapies, escalation of respiratory support, adverse events, patient comfort
Notes Funding/declarations of interest: Study authors declared that research was supported by
an unrestricted grant from Fisher & Paykel Healthcare, but that the sponsors had no
part in the study design and no access to trial data
Study dates: not reported, Conducted over a 14-month period
Note: some additional outcome data retrieved through email contact with study authors
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers in
blocks of 12
Allocation concealment (selection bias) Low risk Sequentially numbered opaque envelopes
prepared by non-study staff
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants or personnel
to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors for atelectasis scoring
blinded to treatment allocation
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition fully reported. Small number of
losses
Selective reporting (reporting bias) High risk ACTRN12610000973011. Prospective
registration in November 2010. Reported
additional outcomes that were not stated
in trial registration records (outcomes in
protocol were SpO2/FiO2 ratio, atelecta-
sis, spirometry, adjunctive respiratory sup-
port therapies, mortality, respiratory com-
plications in hospital and that required visit
to general practitioner in 28 days, patient
comfort)
Other bias Low risk Fisher & Paykel Healthcare provided con-
sumables for intervention arm but had no
part in study design, conduct, analysis, re-
porting, or publication
Rittayamai 2014
Methods Randomized cross-over study, single-centre study
Participants Total number of participants = 17
Setting: respiratory ICU; Bangkok, Thailand
Inclusion criteria: mechanically ventilated patients who were 18 years of age, successfully
weaned by spontaneous breathing, trial with oxygen T-piece or low level of pressure
support for 120 minutes, and ready for endotracheal extubation
Exclusion criteria: haemodynamic instability or decreased level of consciousness; patients
who lacked cooperation, tracheostomized patients, and pregnant women
Baseline characteristics
Age mean (SD): 66.8 (± 13.8) years
Respiratory rate (breaths/min) mean (SD): recorded before each cross-over period: base-
line 1: 20.3 (± 4.5); baseline 2: 21.7 (± 3.8)
PaCO2: not reported
PaO2/FiO2: not reported
Interventions After endotracheal extubation, participants were randomized into either:
1. HFNC
Optiflow system, Fisher & Paykel Healthcare; initial inspiratory flow of 35 L/min, and
FiO2 adjusted to achieve SpO2 ≥ 94% within the first 5 minutes and to maintain this
setting for 30 minutes
2. Non-rebreather face mask
6 to 10 L/min to achieve SpO2 94% for another 30 minutes
Outcomes Dyspnoea, patient comfort, breathing frequency, heart rate blood pressure, SpO2
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Notes Funding/declarations of interest: Study authors did not report funding sources. They
disclosed no conflicts of interest
Study dates: August to December 2011
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods used to generate group allocation
not stated
Allocation concealment (selection bias) Unclear risk Methods of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants or study staff
owing to nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unable to blind outcome assessors owing
to nature of the intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No statement of how many reported. No
participant numbers in tables or graphs
Selective reporting (reporting bias) Unclear risk Trial registrationnot reported in paper.Un-
able to establish whether outcomes were re-
ported according to pre-published protocol
or trial registration documents
SpO2 and mean arterial pressure not re-
ported for all time points set out in meth-
ods
Other bias Low risk No washout period between treatments,
but not a relevant risk of bias for our review
methods. No other sources of bias identi-
fied
Schwabbauer 2014
Methods Randomized cross-over study
Participants Total number of participants = 14
Setting: medical ICU; Germany
Inclusion criteria: patients with hypoxic respiratory failure (PaO2 < 55 mmHg under
room air)
Exclusion criteria: ventilatory failure, haemodynamic instability, cardiogenic pulmonary
oedema, non-invasive ventilation contraindications, inability to co-operate
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Baseline characteristics (recorded before each cross-over period)
Age mean: 55.9 years
Respiratory rate (breaths/min) mean (SD): baseline 1: 28 (± 9); baseline 2: 28 (± 9);
baseline 3: 26 (± 7)
PaCO2 mean (SD): baseline 1: 36 (± 5); baseline 2: 38 (± 5); baseline 3: 37 (± 5)
PaO2/FiO2: not reported
Interventions Participants were treated in randomized order for 30 minutes
1. HFNC
Optiflow system, Fisher & Paykel Healthcare; oxygen flow 55 L/min; FiO2 0.6, using
active respiratory gas humidifier
2. Venturi mask
Oxygen flow 15 L/min; FiO2 0.6
3. Non-invasive ventilation
Intensive care ventilators in pressure support mode; PEEP set to 5 cm H2O; pressure
support above PEEP adjusted individually to achieve tidal volume of 6 to 8 mL/kg ideal
body weight; FiO2 0.6
Each treatment phase was preceded by a 15-minute baseline phase during which par-
ticipants received oxygen via a standard nasal prong (oxygen flow 4 to 12 L/min, SaO2
goal ≥ 88%)
Outcomes PaO2, respiratory rate, dyspnoea (Borg scale), discomfort (10-point scale), PaCO2, heart
rate, blood pressure, SpO2, global rating, patient preference
Notes Funding/declarations of interest: Fisher &PaykelHealthcare provided 2Optiflowdevices
at no charge for the study. Investigators received no financial support and manufacturer
had no part in study design, conduct, analysis, reporting, or publication
Study dates: March 2009 to March 2011
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Order of experimental protocol was randomly assigned,
and assignments of participants to the sequence of the 3
oxygen applicatorswas randomized.However, nodetails
on how this randomization was conducted
Allocation concealment (selection bias) Unclear risk No detail
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants to treatment allocation.No
mention of blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome assessors.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses. Treatment stopped early in 3 par-
ticipants in the NIV group, but data still collected
Selective reporting (reporting bias) Unclear risk DRKS00005132. Retrospectively registered with Ger-
man clinical trials register in July 2013. Not feasible to
assess presence of any risk of selective reporting bias
Other bias Low risk Funding frommanufacturer, which had no involvement
in study design and management
Stephan 2015
Methods Randomized controlled trial, multi-centre study
6 ICUs
Participants Total number of participants = 830
Setting: ICUs; France
Inclusion criteria: patients who had undergone cardiothoracic surgery and had failed
a spontaneous breathing trial, or had preexisting risk factors for post extubation acute
respiratory failure, or had failed extubation
Exclusion criteria: obstructive sleep apnoea, tracheostomy, do-not-intubate status, delir-
ium, nausea and vomiting, bradypnoea, impaired consciousness, haemodynamic insta-
bility
Baseline characteristics
1. HFNC
Age mean (95% CI): 63.8 (62.5 to 65.2) years
Respiratory rate (breaths/min) mean (95% CI): 22.8 (22.1 to 23.5)
PaCO2 mmHg mean (95% CI): 38.7 (38.1 to 39.4):
PaO2/FiO2 mmHg mean (95% CI): 196 (187 to 204)
2. BiPAP
Age mean (95% CI): 63.9 (62.6 to 65.2) years
Respiratory rate (breaths/min) mean (95% CI): 23.3 (22.6 to 24.0)
PaCO2 mmHg mean (95% CI): 39.1 (38.4 to 39.8)
PaO2/FiO2 mmHg mean (95% CI): 203 (195 to 212)
Interventions 1. HFNC; n = 414
Optiflow system at initial flow rate of 50 L/min
2. BiPAP; n = 416
Pressure support started at 8 cm H2O to achieve exhaled tidal volume of 8 mL/kg and
respiratory rate < 25 breaths per minute, via full face mask and ventilatory specifically
designed for BiPAP or ICU ventilator
Initial FiO2 in both groups was 50%, adjusted to maintain SaO2 at 92% to 98%
HFNC was delivered continuously. BiPAP was delivered for 2 hours initially, then for
approximately 1 hour every 4 hours, or more if needed
Outcomes Treatment failure (defined as reintubation for mechanical ventilation, switch to other
study treatment, or premature study treatment discontinuation), respiratory variables,
dyspnoea, comfort, skin breakdown, respiratory and extrapulmonary complications,
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number of bronchoscopies, mortality in ICU
Notes Funding/declarations of interest: Study authors did not report any funding sources. They
disclosed no conflicts of interest
Study dates: June 2011 to January 2014
Respiratory variables and respiratory rate reported at baseline, 1 hour, and 6 to 12 hours.
For meta-analysis in the review, data were taken at 6 to 12 hours
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence in
blocks of 2 or 4
Allocation concealment (selection bias) Unclear risk Use of opaque envelopes but no further de-
tails
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants or personnel
to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Low risk NCT01458444. Study registered retro-
spectively in October 2011 (although early
in study period). All relevant outcomes
were reported as stated in protocol
Other bias Low risk No other sources of bias identified
BiPAP: bilevel positive airway pressure
BMI: body mass index
FiO2: fraction of inspired oxygen
GCS: Glasgow coma score
HFFM: high-flow face mask
HFNC: high-flow nasal cannulae
ICU: intensive care unit
n: number of participants
NIPPV: non-invasive positive-pressure ventilation
NIV: non-invasive ventilation
PaCO2: carbon dioxide clearance
PaO2: partial pressure of arterial oxygen
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PEEP: positive end-expiratory pressure
SaO2: oxygen saturation of arterial blood
SD: standard deviation
SpO2: oxygen saturation
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baneton 2014 Not a randomized controlled trial
Besch 2014 Ancillary study of Stephan 2015, but observational study - not a randomized controlled trial
Braunlich 2013 Not participants of interest
Curley 2015 Not a randomized controlled trial
Parke 2013b No review outcomes of interest
Pinto 2012 Not participants of interest
Simon 2014 Randomized controlled trial with appropriate intervention and comparison but used for oxygenation during
bronchoscopy
Tiruvoipati 2010 Flow rate for comparison intervention was 30 L/min, which is outside the review criteria
Vourc’h 2015 Study of pre-oxygenation methods before intubation
Characteristics of studies awaiting assessment [ordered by study ID]
Futier 2016
Methods RCT. Multi-centre study. France
Participants 220 participants
Interventions HFNC or standard oxygen therapy (low-flow oxygen delivered via nasal prongs or face mask) directly after extubation
Outcomes Hypoxaemia, postoperative pulmonary complicationswithin 7 days after surgery, duration of hospital stay, in-hospital
mortality
Notes
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Methods RCT. Multi-centre study. Three ICUs in Spain
Participants 604 participants at high risk for reintubation
Interventions HFNC or NIV after extubation
Outcomes Reintubation and postextubation respiratory failure within 72 hours, respiratory infection, sepsis, multiple organ
failure, length of stay and mortality; adverse events; time to reintubation
Notes
Hernandez 2016b
Methods RCT. Multi-centre study. Seven ICUs in Spain
Participants 527 participants at low risk for re-intubation
Interventions HFNC or standard oxygen therapy after extubation
Outcomes Re-intubationwithin 72hours, postextubation respiratory failure, respiratory infection, sepsis andmulti-organ failure,
ICU and hospital length of stay, mortality, adverse events, time to reintubation
Notes
Lemiale 2016
Methods RCT. Multi-centre. France and Belgium
Participants 353 immunocompromised participants
Interventions HFNC or NIV
Outcomes Mortality at day 28, intubation rate, duration of mechanical ventilation, ICU-acquired infection, ICU and hospital
length of stay
Notes Post hoc analysis of larger study.
Perbet 2014
Methods RCT. Multi-centre study. Four intensive care units at 2 hospitals
Participants 80 participants
Interventions HFNC or standard oxygenation for 48 hours post extubation
Outcomes Lung ultrasound score, dyspnoea, postextubation distress incidence
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Perbet 2014 (Continued)
Notes Abstract only. Insufficient information on standard oxygenation
Saeed 2015
Methods Not stated if this is RCT. Single-centre
Participants 85 participants with chronic obstructive pulmonary disease
Interventions HFNC or Venturi face mask
Outcomes Arterial blood gas variables, successful weaning, treatment failure
Notes Abstract only. Need to establish if this is an RCT
HFNC: high-flow nasal cannulae
ICU: intensive care unit
NIV: non-invasive ventilation
RCT: randomized controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT01166256
Trial name or title Comparison between high-flow nasal cannula system and non-invasive ventilation in acute hypoxaemic
respiratory failure
Methods Randomized controlled trial
Participants Total number of participants = 74
Inclusion criteria: age ≥ 18 years, acute hypoxaemic respiratory failure
Exclusion criteria: age < 18 years; hypercapnoea (arterial carbon dioxide tension (PaCO2 > 45 mmHg) at
admission); need for emergency intubation, including cardiopulmonary resuscitation;
recent oesophageal, facial, or cranial trauma or surgery; severely decreased consciousness (GCS < 11); car-
diogenic shock or severe haemodynamic instability; systolic blood pressure < 90 mmHg associated with de-
creased urinary output (< 20 mL per hour) despite fluid repletion and use of vasoactive agents; lack of co-
operation; altered mental status with decreased consciousness and/or evidence of inability to understand or
lack of willingness to co-operate with procedures;
tracheotomy or other upper airway disorders; severe ventricular arrhythmia or active myocardial ischaemia;
active upper gastrointestinal bleeding; inability to clear respiratory secretions;
more than 1 severe organ dysfunction in addition to respiratory failure
Interventions Experimental: high-flow nasal cannula. In this arm, acute hypoxaemic respiratory failure treated with high-
flow nasal cannula system (Optiflow, Fisher & Paykel, Auckland, New Zealand) to achieve SpO2 > 92% or
PaO2 > 65 mmHg
Active comparator: non-invasive ventilation. In this arm, participants with acute hypoxaemic respiratory
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NCT01166256 (Continued)
failure are treated with the bilevel positive airway pressure mode (BiPAP Vision, Respironics Inc., Murrysville,
PA) and with S/T mode to achieve SpO2 > 92% or PaO2 > 65 mmHg
Outcomes Primary outcome measures: success rate of treatment in 2 groups (successful treatment is to avoid intubation
and achieve PaO2 > 75mmHg without respiratory distress for 24 hours while spontaneously breathing oxygen
provided by a Venturi device at FiO2 0.50)
Secondary outcome measures: compliance with treatment, withdrawal of non-invasive ventilation or high-
flow nasal cannula system without intubation because of intolerance, adverse event,
hospital length of stay, hospital mortality
Starting date July 2010
Contact information Chae-ManLim,MD,Department of Pulmonary andCritical CareMedicine, AsanMedical Center,University
of Ulsan College of Medicine, Seoul, Korea
Notes ClinicalTrials.gov Identifier: NCT01166256
NCT01617252
Trial name or title High flow nasal oxygen therapy for hypoxaemia after cardiac surgery (Optiflow)
Methods Randomized controlled trial
Participants Total number of participants = 98
Inclusion criteria: indication of coronary artery bypass, absence of preoperative respiratory failure, hypoxia
after extubation defined as SpO2 < 96% with Venturi mask, FiO2 50% 8 L/min, age > 18 years, signed
informed consent
Exclusion criteria: requiring imminent intubation, coma or respiratory exhaustion, state of shock or severe
rhythm disorders, pneumothorax, ventricular arrhythmia, pregnancy, non-controlled hyperalgia
Interventions Experimental: Optiflow
Experimental: facial mask
Outcomes Primary outcome measures: measure of PaO2/FiO2 ratio
Secondary outcome measures: scale of satisfaction completed by participant; measure of pH, SaO2, PaO2/
FiO2 ratio; number of days of hospitalization; measure of PCO2 and respiratory frequency
Starting date June 2011
Contact information Dr Johanna Nicolet, Nantes University Hospital
Notes ClinicalTrials.gov identifier: NCT01617252
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NCT01702779
Trial name or title Nasal humidified high flow oxygen during weaning from mechanical ventilation: ultrasonography study
(HiFloLUS)
Methods Randomized controlled trial
Participants Total number of participants = 80
Inclusion criteria: adult patients ventilated longer than 48 hours, stable respiratory and haemodynamic con-
ditions for spontaneous breathing trial, consent of participants, arterial line
Exclusion criteria: COPD, laryngeal dyspnoea, tracheostomy, arrhythmia, no echogenicity, paraplegia > T8
Interventions Optiflow vs standard oxygen
Outcomes Primary outcome measures: variations in lung ultrasound score
Secondary outcome measures: lung ultrasound score, rates of postextubation distress, electrical Impedance
tomography, epithelial and endothelial biomarkers
Starting date August 2011
Contact information Patrick Lacarin, University Hospital, Clermont-Ferrand, placarin@chu-clermonetferrand.fr
Notes ClinicalTrials.gov identifier: NCT01702779
NCT01782430
Trial name or title PREoxygenation for the intubation of hypoxaemic patients: comparison of standard oxygenation, high flow
nasal oxygen therapy, and nonInvasive ventilation (PREONIV)
Methods Randomized controlled trial, open label
Participants Total number of participants = 144
Inclusion criteria: adults requiring intubation and hypoxaemia (defined by PaO2/FiO2 < 200), covered by
French healthcare system
Exclusion criteria: patient refusal, intubation for other causes (excluding hypoxaemia), impossibility of mea-
suring pulse oxymetry value, contraindication for NIV, vomiting, NIV intolerance, cardiac arrest during
intubation
Interventions Standard oxygenation vs high-flow nasal oxygen therapy vs non-invasive ventilation (NIV)
Outcomes Primary outcome measures: least pulse oximetry value
Secondary outcome measures: pulse oximetry value (at end of pre-oxygenation), PaO2, respiratory rate,
oxyhaemoglobin desaturation < 80%
Starting date April 2013
Contact information Patrick Lacarin, placarin@chu-clermonetferrand.fr
Notes ClinicalTrials.gov Identifier:NCT01782430
50High-flow nasal cannulae for respiratory support in adult intensive care patients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01820507
Trial name or title Extubation failure prevention in high risk patients by high-flow conditioned oxygen therapy vs standard
oxygen therapy
Methods Double-blind randomized controlled trial
Participants Total number of participants = 400
Inclusion criteria: mechanically ventilated for > 48 hours and at least 1 of the following:
aged > 65 years, cardiac failure as primary indication of mechanical ventilation, COPD, severity score
(APACHE II > 12 points) extubation day, BMI > 30, inability to manage respiratory secretions, 1 failed
spontaneous breathing trial, 1 comorbidity, 7 days under mechanical ventilation
Exclusion criteria: aged < 18 years, tracheotomized patients, recent facial or cervical trauma/surgery, active
gastrointestinal bleeding, lack of co-operation, any failed spontaneous breathing trial because of hypercapnia
development
Interventions Experimental: high-flow conditioned oxygen therapy intervention: Optiflow(R) device supplies oxygen in
controlled concentrations and at high flow (from 10 to 70 L/min) through special nasal cannulae. The device
also humidifies the gas mixture up to 100% relative humidity. Active comparator: standard oxygen therapy:
standard way of oxygen supply after extubation is by nasal cannulae at flow between 1 and 5 L/min or by
mask with controlled oxygen concentration from 24% to 50%
Outcomes Primary outcome measures: respiratory failure after extubation, severe hypoxaemia (PaO2/FiO2 < 200),
hypercapnia (PaCO2 > 50), respiratory acidosis (arterial pH < 7.30), severe tachypnoea (> 40 beats perminute)
Secondary outcome measures: survival
Starting date March 2013
Contact information Rafael Fernandez, rfernandezf@althais.cat
Notes ClinicalTrials.gov Identifier: NCT01820507
NCT01994928
Trial name or title Preoxygenation in the intensive care unit using a nose-mouth mask versus high-flow nasal cannula oxygen
Methods Randomized controlled trial, open label
Participants Total number of participants = 50
Inclusion criteria: aged ≥ 18 years, patients treated in an ICU, indication for intubation, presence of hypox-
aemia (SaO2/FiO2: ≤ 300), respiratory failure, informed consent
Exclusion criteria: blocked nasopharynx, contraindications for nose-mouth mask or high-flow nasal cannula
oxygen, expected difficult airway
Interventions Active comparator: nose-mouth mask; performance of intubation after pre-oxygenation using a nose-mouth
mask
Experimental: high-flow nasal cannula oxygen; performance of intubation after pre-oxygenation using high-
flow nasal cannula oxygen
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NCT01994928 (Continued)
Outcomes Primary outcome measures: mean decrease in SpO2 during intubation
Secondary outcome measures: changes in blood gases after intubation, changes in haemodynamics
Starting date November 2013
Contact information Stefan Kluge, skluge@uke.de
Notes ClinicalTrials.gov Identifier: NCT01994928
NCT02107183
Trial name or title Impact of nasal high-flow vs Venturi mask oxygen therapy on weaning outcome: a multicenter, randomized,
controlled trial (RINO)
Methods Randomized controlled trial, open label
Participants Total number of participants = 500
Inclusion criteria: age ≥ 18 years, mechanical ventilation > 24 hours, signed informed consent, successful
spontaneous breathing trial, PaO2/FiO2 ratio ≤ 300 (or SpO2/FiO2 ratio ≤ 300 if SpO2 < 98%) within 30
minutes after extubation while breathing through a Venturi mask with a delivered FiO2 of 30%
Exclusion criteria: pregnancy, presence of tracheostomy, need for immediate postextubation non-invasive
ventilation (> 3 consecutive failures of the spontaneous breathing trial and/or PaCO2 > 45 mmHg before
spontaneous breathing trial, with respiratory rate ≥ 25/min)
Interventions Experimental: nasal high-flow oxygen therapy; high-flow, fully humidified oxygen delivered through nasal
cannula (Optiflow, Fisher & Paykel Healthcare) after extubation up to ICU discharge Active comparator:
Venturi mask oxygen therapy; oxygen delivered through standard Venturi mask after extubation up to ICU
discharge
Outcomes Primary outcome measure: reintubation
Secondary outcome measures: need for NIV, ICU length of stay, hospital length of stay, ICU re-admission,
ICU mortality, hospital mortality
Starting date June 2014
Contact information Salvatore Maurizio Maggiore, smmaggiore@rm.unicatt.it
Notes ClinicalTrials.gov Identifier: NCT02107183
NCT02123940
Trial name or title Treatment strategy in patients with high-risk of postextubation distress in ICU based on a lung ultrasound
score versus standard strategy (WIN IN WEAN)
Methods Randomized controlled trial
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NCT02123940 (Continued)
Participants Total number of participants = 640
Inclusion criteria: adult patients ventilated > 48 hours, stable respiratory and haemodynamic conditions for
SBT, consent of patients, arterial line
Exclusion criteria: severe COPD, laryngeal dyspnoea, tracheostomy, arrhythmia, no echogenicity, paraplegia
> T8
Interventions Comparing a treatment strategy (nasal humidified high-flow therapy and non-invasive ventilation) in patients
with high risk of postextubation distress in ICU based on a lung ultrasound score vs standard strategy
Outcomes Primary outcome measures: incidence of postextubation distress, postextubation period requiring ventilatory
support (reintubation or curative non-invasive ventilation)
Secondary outcome measures: number of ventilator-free-days, length of stay in ICU, mortality in ICU
Starting date February 2014
Contact information Patrick Lacarin, placarin@chu-clermonetferrand.fr
Notes ClinicalTrials.gov Identifier: NCT02123940
UMIN000008778
Trial name or title Evaluation of nasal high flow oxygen therapy for severe acute hypoxaemic respiratory failure
Methods Randomized controlled trial
Participants Total number of randomized participants = 40
Inclusion criteria: admitted to respiratory department of our hospital for severe AHRF other than cardiogenic
pulmonary edema, met the standard clinical and/or blood gas criteria for use of non-invasive ventilation to
treat severe AHRF, received NIV for < 12 hours
Exclusion criteria: hypercapnoea (PaCO2 > 45mmHg), unstable clinical conditions (i.e. need for vasopressors,
metabolic acidosis, life-threatening arrhythmias, need for FiO≥ 0.8, agitation and anxiety), inability to obtain
consent, face or neck deformities, use of NIV before admission, need for continuous sedation
Interventions Nasal high-flow oxygen therapy
Non-invasive ventilation
Outcomes Primary outcome: interface discomfort
Secondary outcomes: dyspnoea, easy to speak, sleep perception, easy to eat and drink, arterial blood gas
analysis, vital signs, early failure, length of ICU stay, length of hospital stay, in-hospital mortality, 90-day
survival, complications
Starting date September 2012
Contact information Kazuma Nagata, Kobe City Medical Center General Hospital, kazuma n1101@yahoo.co.jp
Notes Clinical trials register ID: UMIN000008778
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AHRF: acute hypoxic respiratory failure
APACHE: Acute Physiology and Chronic Health Evaluation
BiPAP: bilevel positive airway pressure
BMI: body mass index
COPD: chronic obstructive pulmonary disease
FiO2: fraction of inspired oxygen
GCS: Glasgow coma score
ICU: intensive care unit
NIV: non-invasive ventilation
PaCO2: carbon dioxide clearance
PaO2: partial pressure of arterial oxygen
PCO2: partial pressure of carbon dioxide
SaO2: oxygen saturation
SBT: spontaneous breathing trial
SpO2: oxygen saturation
S/T: spontaneous/timed
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D A T A A N D A N A L Y S E S
Comparison 1. High-flow nasal cannulae versus low-flow oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failure of treatment as indicated
by the need for NIPPV or
invasive ventilation
6 1066 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.49, 1.27]
Comparison 2. High-flow nasal cannulae versus low-flow oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 In-hospital mortality 3 755 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.38, 1.06]
Comparison 3. High-flow nasal cannulae versus low-flow oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Length of ICU stay 4 770 Mean Difference (IV, Random, 95% CI) 0.15 [-0.03, 0.34]
Comparison 4. High-flow nasal cannulae versus low-flow oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PaO2/FiO2 ratio up to 24 hours
after initiation of therapy
4 510 Mean Difference (IV, Random, 95% CI) 7.31 [-26.69, 41.31]
2 PaO2 up to 24 hours after
initiation of therapy
3 355 Mean Difference (IV, Random, 95% CI) 2.79 [-5.47, 11.05]
3 SpO2 up to 24 hours after
initiation of therapy
4 512 Mean Difference (IV, Random, 95% CI) 0.72 [-0.73, 2.17]
4 SpO2 at > 24 hours after
initiation of therapy
2 445 Mean Difference (IV, Random, 95% CI) 1.28 [0.02, 2.55]
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Comparison 5. High-flow nasal cannulae versus low-flow oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PaCO2 up to 24 hours 3 590 Mean Difference (IV, Random, 95% CI) -0.75 [-2.04, 0.55]
Comparison 6. High-flow nasal cannulae versus low-flow oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Respiratory rate up to 24 hours
after initiation of therapy
(short-term effects)
6 867 Mean Difference (IV, Random, 95% CI) -1.51 [-3.36, 0.35]
2 Respiratory rate > 24 hours
after initiation of therapy
(longer-term effects)
2 445 Mean Difference (IV, Random, 95% CI) -2.71 [-7.12, 1.70]
Comparison 7. High-flow nasal cannulae versus CPAP/BiPAP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Respiratory rate up to 24 hours 2 834 Mean Difference (IV, Random, 95% CI) -0.89 [-1.74, -0.05]
Comparison 8. High-flow nasal cannulae versus low-flow oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Comfort (short-term effect) 3 462 Mean Difference (IV, Random, 95% CI) 0.14 [-0.65, 0.93]
2 Comfort (long-term effect) 2 445 Mean Difference (IV, Random, 95% CI) -0.36 [-3.70, 2.98]
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Comparison 9. High-flow nasal cannulae versus low-flow oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failure of treatment: subgroup
by reason for respiratory
support
6 1066 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.49, 1.27]
1.1 Respiratory failure 3 466 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.56, 1.11]
1.2 Post extubation 3 600 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.17, 4.21]
Analysis 1.1. Comparison 1 High-flow nasal cannulae versus low-flow oxygen, Outcome 1 Failure of
treatment as indicated by the need for NIPPV or invasive ventilation.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 1 High-flow nasal cannulae versus low-flow oxygen
Outcome: 1 Failure of treatment as indicated by the need for NIPPV or invasive ventilation
Study or subgroup
High flow
nasal
cannulae Low flow oxygen Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Corley 2014 3/81 2/74 5.8 % 1.37 [ 0.24, 7.97 ]
Frat 2015 (1) 20/53 55/110 24.5 % 0.75 [ 0.51, 1.12 ]
Frat 2015 (2) 20/53 44/94 24.2 % 0.81 [ 0.54, 1.21 ]
Lemiale 2015 (3) 8/52 4/48 10.9 % 1.85 [ 0.59, 5.74 ]
Maggiore 2014 4/53 18/52 12.5 % 0.22 [ 0.08, 0.60 ]
Parke 2011 3/29 8/27 9.9 % 0.35 [ 0.10, 1.18 ]
Parke 2013a 11/169 5/171 12.2 % 2.23 [ 0.79, 6.27 ]
Total (95% CI) 490 576 100.0 % 0.79 [ 0.49, 1.27 ]
Total events: 69 (High flow nasal cannulae), 136 (Low flow oxygen)
Heterogeneity: Tau2 = 0.20; Chi2 = 14.36, df = 6 (P = 0.03); I2 =58%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours HFNC Favours low flow oxygen
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(1) HFNC vs noninvasive ventilation (data in HFNC group has been halved)
(2) HFNC vs standard (data in HFNC group has been halved)
(3) within 2 hours
Analysis 2.1. Comparison 2 High-flow nasal cannulae versus low-flow oxygen, Outcome 1 In-hospital
mortality.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 2 High-flow nasal cannulae versus low-flow oxygen
Outcome: 1 In-hospital mortality
Study or subgroup
High flow
nasal
cannulae Low flow oxygen Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Frat 2015 (1) 6/53 18/94 36.0 % 0.59 [ 0.25, 1.40 ]
Frat 2015 (2) 6/53 27/110 39.4 % 0.46 [ 0.20, 1.05 ]
Maggiore 2014 (3) 6/53 5/52 21.1 % 1.18 [ 0.38, 3.62 ]
Parke 2013a 1/169 1/171 3.5 % 1.01 [ 0.06, 16.05 ]
Total (95% CI) 328 427 100.0 % 0.63 [ 0.38, 1.06 ]
Total events: 19 (High flow nasal cannulae), 51 (Low flow oxygen)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.88, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours HFNC Favours low flow oxygen
(1) HFNC vs standard oxygen (data in HFNC has been halved). In ICU
(2) HFNC vs noninvasive ventilation (data in HFNC group has been halved). In ICU
(3) At ICU discharge
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Analysis 3.1. Comparison 3 High-flow nasal cannulae versus low-flow oxygen, Outcome 1 Length of ICU stay.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 3 High-flow nasal cannulae versus low-flow oxygen
Outcome: 1 Length of ICU stay
Study or subgroup
High flow
nasal
cannulae Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Frat 2015 (1) 94 10.7 (15.8) 76 9.1 (11.7) 0.2 % 1.60 [ -2.54, 5.74 ]
Maggiore 2014 53 11.7 (10.2) 52 10.4 (8.5) 0.3 % 1.30 [ -2.29, 4.89 ]
Corley 2014 81 1.61 (1.47) 74 1.61 (1) 21.7 % 0.0 [ -0.39, 0.39 ]
Parke 2013a 169 1.39 (0.95) 171 1.2 (1) 77.9 % 0.19 [ -0.02, 0.40 ]
Total (95% CI) 397 373 100.0 % 0.15 [ -0.03, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.57, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.098)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours HFNC Favours low flow oxygen
(1) survivors at 90 days (standard oxygen therapy)
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Analysis 4.1. Comparison 4 High-flow nasal cannulae versus low-flow oxygen, Outcome 1 PaO2/FiO2 ratio
up to 24 hours after initiation of therapy.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 4 High-flow nasal cannulae versus low-flow oxygen
Outcome: 1 PaO2/FiO2 ratio up to 24 hours after initiation of therapy
Study or subgroup
High flow
nasal
cannulae Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Corley 2014 (1) 81 281.4 (85.6659) 74 253.3 (85.6659) 24.8 % 28.10 [ 1.10, 55.10 ]
Frat 2015 (2) 106 130 (60) 94 161 (77) 26.8 % -31.00 [ -50.31, -11.69 ]
Maggiore 2014 (3) 53 287.5 (74.3) 52 247.4 (80.6) 24.0 % 40.10 [ 10.43, 69.77 ]
Parke 2011 (4) 28 177.8 (50.2) 22 181.7 (50.3) 24.5 % -3.90 [ -31.96, 24.16 ]
Total (95% CI) 268 242 100.0 % 7.31 [ -26.69, 41.31 ]
Heterogeneity: Tau2 = 1025.70; Chi2 = 21.15, df = 3 (P = 0.00010); I2 =86%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours low flow oxygen Favours HFNC
(1) first 24 hours
(2) HFNC vs standard oxygen therapy (at 6 hours)
(3) At 24 hours
(4) At four hours
60High-flow nasal cannulae for respiratory support in adult intensive care patients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.2. Comparison 4 High-flow nasal cannulae versus low-flow oxygen, Outcome 2 PaO2 up to 24
hours after initiation of therapy.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 4 High-flow nasal cannulae versus low-flow oxygen
Outcome: 2 PaO2 up to 24 hours after initiation of therapy
Study or subgroup
High flow
nasal
cannulae Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Frat 2015 (1) 106 90 (35) 94 93 (36) 35.0 % -3.00 [ -12.87, 6.87 ]
Maggiore 2014 (2) 53 95 (28) 52 84.6 (22.6) 35.5 % 10.40 [ 0.68, 20.12 ]
Parke 2011 (3) 28 80.2 (11.8) 22 79.7 (25.6) 29.5 % 0.50 [ -11.06, 12.06 ]
Total (95% CI) 187 168 100.0 % 2.79 [ -5.47, 11.05 ]
Heterogeneity: Tau2 = 25.42; Chi2 = 3.82, df = 2 (P = 0.15); I2 =48%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours HFNC Favours low flow oxygen
(1) HFNC vs standard oxygen (at 6 hours)
(2) At 24 hours
(3) At four hours
61High-flow nasal cannulae for respiratory support in adult intensive care patients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 High-flow nasal cannulae versus low-flow oxygen, Outcome 3 SpO2 up to 24
hours after initiation of therapy.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 4 High-flow nasal cannulae versus low-flow oxygen
Outcome: 3 SpO2 up to 24 hours after initiation of therapy
Study or subgroup
High flow
nasal
cannulae Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Maggiore 2014 (1) 53 97 (2) 52 95 (2) 27.6 % 2.00 [ 1.23, 2.77 ]
Parke 2011 (2) 28 95 (2) 22 95.4 (2.9) 23.3 % -0.40 [ -1.82, 1.02 ]
Parke 2013a (3) 169 96.6 (2.1) 171 96.9 (1.9) 29.2 % -0.30 [ -0.73, 0.13 ]
Rittayamai 2014 (4) 9 99.11 (1.45) 8 97.38 (2.34) 19.9 % 1.73 [ -0.15, 3.61 ]
Total (95% CI) 259 253 100.0 % 0.72 [ -0.73, 2.17 ]
Heterogeneity: Tau2 = 1.83; Chi2 = 29.69, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours HFNC Favours low flow oxygen
(1) At 24 hours
(2) At four hours
(3) At day 1
(4) At 30 minutes
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Analysis 4.4. Comparison 4 High-flow nasal cannulae versus low-flow oxygen, Outcome 4 SpO2 at > 24
hours after initiation of therapy.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 4 High-flow nasal cannulae versus low-flow oxygen
Outcome: 4 SpO2 at > 24 hours after initiation of therapy
Study or subgroup
High flow
nasal
cannulae Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Maggiore 2014 (1) 53 97 (2) 52 95 (3) 45.0 % 2.00 [ 1.02, 2.98 ]
Parke 2013a (2) 169 95.6 (2.6) 171 94.9 (2.6) 55.0 % 0.70 [ 0.15, 1.25 ]
Total (95% CI) 222 223 100.0 % 1.28 [ 0.02, 2.55 ]
Heterogeneity: Tau2 = 0.68; Chi2 = 5.15, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours HFNC Favours low flow oxygen
(1) At 48 hours
(2) At day 2
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Analysis 5.1. Comparison 5 High-flow nasal cannulae versus low-flow oxygen, Outcome 1 PaCO2 up to 24
hours.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 5 High-flow nasal cannulae versus low-flow oxygen
Outcome: 1 PaCO2 up to 24 hours
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Frat 2015 (1) 106 36 (7) 94 36 (6) 31.6 % 0.0 [ -1.80, 1.80 ]
Parke 2011 28 40.6 (6) 22 39.8 (6.3) 12.0 % 0.80 [ -2.65, 4.25 ]
Parke 2013a (2) 169 38.2 (4.95) 171 39.7 (4) 56.4 % -1.50 [ -2.46, -0.54 ]
Total (95% CI) 303 287 100.0 % -0.75 [ -2.04, 0.55 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 3.26, df = 2 (P = 0.20); I2 =39%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours HFNC Favours low flow oxygen
(1) HFNC versus standard oxygen
(2) At day 1
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Analysis 6.1. Comparison 6 High-flow nasal cannulae versus low-flow oxygen, Outcome 1 Respiratory rate
up to 24 hours after initiation of therapy (short-term effects).
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 6 High-flow nasal cannulae versus low-flow oxygen
Outcome: 1 Respiratory rate up to 24 hours after initiation of therapy (short-term effects)
Study or subgroup
High flow
nasal
cannulae Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Corley 2014 (1) 81 17.24 (2.38) 74 16.7 (2.38) 21.4 % 0.54 [ -0.21, 1.29 ]
Frat 2015 (2) 106 27 (7) 94 29 (8) 17.3 % -2.00 [ -4.10, 0.10 ]
Maggiore 2014 (3) 53 21 (4) 52 26 (5) 18.6 % -5.00 [ -6.73, -3.27 ]
Parke 2011 (4) 28 17 (7) 22 16 (8) 10.3 % 1.00 [ -3.23, 5.23 ]
Parke 2013a (5) 169 16.6 (4.9) 171 16.9 (5.1) 20.7 % -0.30 [ -1.36, 0.76 ]
Rittayamai 2014 (6) 9 19.8 (3.2) 8 23.1 (4.4) 11.8 % -3.30 [ -7.00, 0.40 ]
Total (95% CI) 446 421 100.0 % -1.51 [ -3.36, 0.35 ]
Heterogeneity: Tau2 = 4.05; Chi2 = 38.04, df = 5 (P<0.00001); I2 =87%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours HFNC Favours low flow oxygen
(1) first 24 hours
(2) HFNC versus standard oxygen (at 6 hours)
(3) At 24 hours
(4) at four hours
(5) At day 1
(6) at 30 minutes
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Analysis 6.2. Comparison 6 High-flow nasal cannulae versus low-flow oxygen, Outcome 2 Respiratory rate >
24 hours after initiation of therapy (longer-term effects).
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 6 High-flow nasal cannulae versus low-flow oxygen
Outcome: 2 Respiratory rate > 24 hours after initiation of therapy (longer-term effects)
Study or subgroup
High flow
nasal
cannulae Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Maggiore 2014 (1) 53 21 (3) 52 26 (4) 49.0 % -5.00 [ -6.35, -3.65 ]
Parke 2013a (2) 169 16.9 (2.7) 171 17.4 (2.6) 51.0 % -0.50 [ -1.06, 0.06 ]
Total (95% CI) 222 223 100.0 % -2.71 [ -7.12, 1.70 ]
Heterogeneity: Tau2 = 9.84; Chi2 = 36.15, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours [experimental] Favours [control]
(1) At 48 hours
(2) At day 2
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Analysis 7.1. Comparison 7 High-flow nasal cannulae versus CPAP/BiPAP, Outcome 1 Respiratory rate up
to 24 hours.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 7 High-flow nasal cannulae versus CPAP/BiPAP
Outcome: 1 Respiratory rate up to 24 hours
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Chanques 2013 (1) 1 20 (6.3) 3 19 (9) 0.3 % 1.00 [ -15.01, 17.01 ]
Stephan 2015 (2) 414 21.6 (6.2105) 416 22.5 (6.2256) 99.7 % -0.90 [ -1.75, -0.05 ]
Total (95% CI) 415 419 100.0 % -0.89 [ -1.74, -0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours HFNC Favours CPAP/BiPAP
(1) Measured at end of treatment
(2) at 6-12 hours
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Analysis 8.1. Comparison 8 High-flow nasal cannulae versus low-flow oxygen, Outcome 1 Comfort (short-
term effect).
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 8 High-flow nasal cannulae versus low-flow oxygen
Outcome: 1 Comfort (short-term effect)
Study or subgroup HFNC Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Maggiore 2014 (1) 53 5.2 (3.4) 52 5.6 (3.5) 23.7 % -0.40 [ -1.72, 0.92 ]
Parke 2013a (2) 169 2.5 (2.6) 171 1.9 (1.8) 56.3 % 0.60 [ 0.12, 1.08 ]
Rittayamai 2014 (3) 9 1.11 (1.37) 8 1.63 (1.73) 20.0 % -0.52 [ -2.02, 0.98 ]
Total (95% CI) 231 231 100.0 % 0.14 [ -0.65, 0.93 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 3.54, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours HFNC Favours low flow
(1) at 1 hour
(2) at 4 hours
(3) at 30 minutes
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Analysis 8.2. Comparison 8 High-flow nasal cannulae versus low-flow oxygen, Outcome 2 Comfort (long-
term effect).
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 8 High-flow nasal cannulae versus low-flow oxygen
Outcome: 2 Comfort (long-term effect)
Study or subgroup HFNC Low flow oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Maggiore 2014 (1) 53 1.5 (1.9) 52 3.6 (3.4) 49.0 % -2.10 [ -3.16, -1.04 ]
Parke 2013a (2) 169 3.06 (2.5) 171 1.75 (1.9) 51.0 % 1.31 [ 0.84, 1.78 ]
Total (95% CI) 222 223 100.0 % -0.36 [ -3.70, 2.98 ]
Heterogeneity: Tau2 = 5.64; Chi2 = 33.36, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours [experimental] Favours [control]
(1) At 48 hours
(2) At day 2
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Analysis 9.1. Comparison 9 High-flow nasal cannulae versus low-flow oxygen, Outcome 1 Failure of
treatment: subgroup by reason for respiratory support.
Review: High-flow nasal cannulae for respiratory support in adult intensive care patients
Comparison: 9 High-flow nasal cannulae versus low-flow oxygen
Outcome: 1 Failure of treatment: subgroup by reason for respiratory support
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Respiratory failure
Frat 2015 (1) 20/53 44/94 24.2 % 0.81 [ 0.54, 1.21 ]
Frat 2015 (2) 20/53 55/110 24.5 % 0.75 [ 0.51, 1.12 ]
Lemiale 2015 (3) 8/52 4/48 10.9 % 1.85 [ 0.59, 5.74 ]
Parke 2011 3/29 8/27 9.9 % 0.35 [ 0.10, 1.18 ]
Subtotal (95% CI) 187 279 69.6 % 0.79 [ 0.56, 1.11 ]
Total events: 51 (Experimental), 111 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.94, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Post extubation
Corley 2014 3/81 2/74 5.8 % 1.37 [ 0.24, 7.97 ]
Maggiore 2014 4/53 18/52 12.5 % 0.22 [ 0.08, 0.60 ]
Parke 2013a 11/169 5/171 12.2 % 2.23 [ 0.79, 6.27 ]
Subtotal (95% CI) 303 297 30.4 % 0.84 [ 0.17, 4.21 ]
Total events: 18 (Experimental), 25 (Control)
Heterogeneity: Tau2 = 1.61; Chi2 = 10.43, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 490 576 100.0 % 0.79 [ 0.49, 1.27 ]
Total events: 69 (Experimental), 136 (Control)
Heterogeneity: Tau2 = 0.20; Chi2 = 14.36, df = 6 (P = 0.03); I2 =58%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
0.01 0.1 1 10 100
Favours HFNC Favours low flow oxygen
(1) HFNC vs standard (data in HFNC group has been halved)
(2) HFNC vs noninvasive ventilation (data in HFNC group has been halved)
(3) within 2 hours
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A D D I T I O N A L T A B L E S
Table 1. Dichotomous outcomes from single studies (HFNC vs BiPAP)
Outcome Total N Intervention n/N Control n/N P value (as reported by study
authors)
Study
Failure of treatment 830 58/414 57/416 0.99 Stephan 2015
Mortality 830 28/414 23/416 0.66 Stephan 2015
Adverse
events - nosocomial
pneumonia
830 83/414 98/516 0.57 Stephan 2015
Adverse events -
pneumothorax
830 8/414 7/416 0.86 Stephan 2015
Ad-
verse events - acute
colonic pseudo-ob-
struction
830 9/414 8/416 0.86 Stephan 2015
N: total number of participants
n: number of participants who had an event
P: significance level
Table 2. Dichotomous outcomes from single studies (HFNC vs low-flow oxygen)
Outcome Total N Intervention
n/N
Control n/N P value (as reported by
study authors)
Study
Adverse
events - nosocomial
pneumonia
310 4/106 Standard: 8/94
NIV: 9/110
0.32 Frat 2015
Adverse events - sep-
tic shock
310 19/106 Standard: 26/94
NIV: 34/110
0.08 Frat 2015
Adverse events - car-
diac dysrhythmia
310 11/106 Standard: 16/94
NIV: 17/110
0.35 Frat 2015
Adverse events - car-
diorespiratory arrest
310 5/106 Standard: 7/94
NIV: 6/110
0.70 Frat 2015
Adverse events - at
least 1 episode of
oxygen desaturation
35* 8/19 10/14 0.009 Parke 2011
71High-flow nasal cannulae for respiratory support in adult intensive care patients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Dichotomous outcomes from single studies (HFNC vs low-flow oxygen) (Continued)
Adverse events - in-
cidence of respira-
tory complications
up to day 28 (GP
visits)
340 13 15 Not reported Parke 2013a
Patient-reported
outcome - refusal to
continue with treat-
ment - excess heat/
discomfort
340 20/171 0/169 Not reported Parke 2013a
* Data available for only 35 participants
GP: general practitioner
HFNC: high-flow nasal cannulae
N: total number of participants
n: number of participants who had an event
NIV: non-invasive ventilation group
P: significance level
Table 3. Continuous outcomes from single studies (HFNC vs low-flow oxygen)
Outcome Total N Intervention Control P values (as reported
by study authors)
Study
Duration of respira-
tory support (hours)
340 Mean (SD) 59.0 (30.8) Mean (SD) 65.0 (41.6) 0.13 Parke 2013a
Atelectasis (ra-
diological atelectasis
score)
155 Day 1: median (IQR)
2 (1.5 to 2.5)
Day 5: median (IQR)
2 (1.5 to 2.5)
Day 1: median (IQR)
2 (1.5 to 3)
Day 5: median (IQR)
2 (1 to 2.5)
Day 1: 0.70
Day 5: 0.15
Corley 2014
Atelectasis (chest X-
ray)
340 Day 1: mean (SD) 4.8
(1.9)
Day 3: mean (SD) 4.8
(1.9)
Day 1: mean (SD) 4.9
(1.8)
Day 3 mean (SD) 4.7
(2.1)
Day 1: 0.63
Day 3: 0.69
Parke 2013a
PaO2/FiO2 at 36
hours (mmHg)
105 Mean (SD) 310.8 (80.
6)
Mean (SD) 233.2 (75.
8)
0.0003 Maggiore 2014
PaO2/FiO2 at 48
hours (mmHg)
105 Mean (SD) 313.3 (83.
8)
Mean (SD) 250.2
(110.1)
0.01 Maggiore 2014
PaO2 at 36 hours
(mmHg)
105 Mean (SD) 97.5 (29.2) Mean (SD) 85.4 (16.3) 0.04 Maggiore 2014
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Table 3. Continuous outcomes from single studies (HFNC vs low-flow oxygen) (Continued)
Respiratory
rate at 120 minutes
(breaths perminute)
100 Median (IQR) 25 (22
to 29)
Median (IQR) 25 (21
to 31)
Not reported Lemiale 2015
Patient comfort at
120 minutes. Scale
of 0 to 10 (0 = ab-
sence of discomfort,
10 = worst possible
discomfort)
100 Median (IQR) 3 (1 to
5)
Median (IQR) 3 (0 to
5)
0.88 Lemiale 2015
Patient-reported
mouth dryness (on a
scale of 0 to 10; 0
= no dryness, 10 =
maximum dryness)
105 Mean (SD) 3.6 (2.5) Mean (SD) 5 (3.1) 0.016 Maggiore 2014
HFNC: high-flow nasal cannulae
IQR: interquartile range
N: Total number of participants
P: significance level
PaO2/FiO2: ratio of partial pressure of arterial oxygen to fraction of inspired oxygen
SD: standard deviation
Table 4. Continuous outcomes for single studies (HFNC vs BiPAP)
Outcome Total N Intervention Control P value Study
Length of stay in
ICU (days)
830 Median (IQR) 6 (4 to
10)
Median (IQR) 6 (4 to
10)
0.77 Stephan 2015
Length of stay in
hospital (days)
830 Median (IQR) 13 (9 to
22)
Median (IQR) 14 (9 to
20)
0.59 Stephan 2015
PaO2/FiO2 (6 to 12
hours)
830 Mean (95% CI) 198
(187 to 208)
Mean (95% CI) 261
(248 to 274)
< 0.001 Stephan 2015
PaCO2mmHg(6 to
12 hours)
830 Mean (95% CI) 38.2
(37.6 to 38.9)
Mean (95% CI) 39.3
(38.6 to 40.0)
0.19 Stephan 2015
Patient comfort at
1 hour. Five-point
scale of ’poor’, ’ac-
ceptable’, or ’good’
830 Poor: 16.7%
Acceptable: 31.0%
Good: 51.0%
Poor: 17.8%
Acceptable: 29.3%
Good: 53.0%
0.32 Stephan 2015
CI: confidence interval
ICU: intensive care unit
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IQR: interquartile range
N: total number of participants
P: significance level
PaCO2: carbon dioxide clearance
PaO2/FiO2: ratio of partial pressure of arterial oxygen to fraction of inspired oxygen
A P P E N D I C E S
Appendix 1. CENTRAL (the Cochrane Library) search strategy
#1 (((high flow or highflow or nasal*) near can?ul*) or HFNC or (nasal near (high flow highflow or prong)) or Vapotherm or Optiflow)
Appendix 2. Search strategy for MEDLINE (OvidSP)
1 (((high flow or highflow or nasal*) adj6 can?ul*) or HFNC or (nasal adj6 (high flow or highflow or prong)) or Vapotherm or
Optiflow).af.
2 ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or
trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.
3 1 and 2
Appendix 3. CINAHL (EBSCO host) search strategy
S1 (((high flow or highflow or nasal*) N3 can?ul*) or HFNC or (nasal N3 (high flow or highflow or prong)) or Vapotherm or Optiflow)
S2 ( (random* or (trial* N3 (controlled or clinical)) or placebo* or prospective or multicenter) or ((blind* or mask*) N3 (single or
double or triple or treble)) )
S3 S1 and S2
Appendix 4. Embase (OvidSP) search strategy
1. (((high flow or highflow or nasal*) adj6 can?ul*) or HFNC or (nasal adj6 (high flow or highflow or prong)) or Vapotherm or
Optiflow).af.
2. (randomized-controlled-trial/ or randomization/ or controlled-study/ or multicenter-study/ or phase-3-clinical-trial/ or phase-4-
clinical-trial/ or double-blind-procedure/ or single-blind-procedure/ or (random* or cross?over* ormulticenter* or factorial* or placebo*
or volunteer*).mp. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti,ab. or (latin adj square).mp.) not (animals not
(humans and animals)).sh.
3. 1 and 2
74High-flow nasal cannulae for respiratory support in adult intensive care patients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 5. ISI Web of Science search strategy
#1 TS=(((high flow or highflow or nasal*) SAME can?ul*) or HFNC or (nasal SAME (high flow or highflow or prong)) or Vapotherm
or Optiflow)
#2 TS=(random* or (trial* SAME (controlled or clinical)) or placebo* or prospective or multicenter) or TS=((blind* or mask*) SAME
(single or double or triple or treble))
#3 #1 and #2
Appendix 6. Study selection form
Study Details
First Author
Journal / Place of publication
Year
Study Eligibility Comments
Study Type
- RCT
- Randomized crossover
Yes / No / Unclear
Relevant participants
- Age ≥ 16 years
- Admitted to intensive care
unit
Yes / No / Unclear
Relevant interventions
- HFNC compared
with comparison interventions
(LFNC, face mask, CPAP, BiPAP)
Yes / No / Unclear
Relevant outcomes
Failure of treatment as indicated
by the need for NIPPV or invasive
ventilation (up to 28 days)
In hospital mortality (up to 90
days)
Adverse events
Duration in hours of any form
of respiratory support (mechan-
ical ventilation, NIPPV, HFNC,
standard oxygen)
Length of stay in days (ICU and
hospital)
Respiratory effects as indicated by
any of the following:
• Degree of atelectasis on
Yes / No / Unclear
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(Continued)
radiological examination
• Positive end expiratory
pressure measured at the
pharyngeal level (cmH2O)
• Oxygenation (PaO2/FiO2
ratio, PaO2, SaO2 and SpO2)
• Carbon dioxide clearance
(PaCO2 and pCO2)
• Respiratory rate
• Work of breathing (joules
per litre)
Patient reported outcomes as indi-
cated by any of the following:
• Dyspnoea
• Comfort
• Mouth dryness
• Patient refusal to continue
with treatment
Cost comparison of treatment (in
Australian dollars)
Appendix 7. Data extraction form
Data extraction form
Review title or ID
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies)
1. General Information
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Date form completed (dd/mm/yyyy)
Name of person extracting data
Report title
(title of paper/ abstract/ report that data are extracted from)
Report ID
(ID for this paper/ abstract/ report)
Reference details
Report author contact details
Publication type
(full report, abstract, letter)
Study funding sources
(including role of funders)
Possible conflicts of interest
(for study authors)
Notes: Notes:
2. Population and setting
Description
Include comparative information for each
group (i.e. intervention and controls) if
available
Location in text
(pg & fig/table)
Population description
(from which study participants
are drawn)
Setting
Including:
· Country of study
· Level of Hospital (Tertiary,
Metropolitan, Regional, Rural)
· Number of beds
Inclusion criteria
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(Continued)
Exclusion criteria
Method/s of recruitment of
participants
Informed consent obtained Yes/No/Unclear
Notes: Notes:
3. Methods
Descriptions as stated in report/paper Location in text
(pg & fig/table)
Aim/s of study
Design (e.g. parallel, cross-over)
Start date
End date
Total study duration
Ethical approval needed/obtained for
study
Yes/No/Unclear
Notes: Notes:
4. Participants
Provide overall data and, if available, comparative data for each intervention or comparison group.
Description as stated in report/paper Location in text
(pg & fig/table)
Total no. randomized
Baseline imbalances
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(Continued)
Withdrawals and exclusions
(if not provided below in results section)
Age range
Sex
Severity of illness
(ARDS/ALI criteria, APACHE score, SOFA
score)
Co-morbidities
(if detailed)
Other treatment received (additional to
study intervention)
Subgroups measured
Subgroups reported
Notes: Notes:
5. Intervention groups
Copy and paste table for each intervention and comparison group.
Intervention Group
Description as stated in report/paper Location in text
(pg & fig/table)
Group name
No. randomized to group
Description of therapy
· Type of delivery device [Vapotherm/Opti-
flow/other]
· Size of nasal cannula
· Litres/ minute delivered
Duration of treatment period
Co-interventions
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(Continued)
Notes: Notes:
Comparison Group 1
Description as stated in report/paper Location in text
(pg & fig/table)
Group name
No. randomized to group
Description of therapy
· Type of delivery device [Vapotherm/Opti-
flow/other]
· Size of nasal cannula
· Litres/ minute delivered
Duration of treatment period
Co-interventions
Notes: Notes:
Add another table if more than one comparison group
6. Outcomes
Outcomes measures reported in paper (circle) Outcomes measur
Failure of treatment as indicated by the need forNIPPVor invasive
ventilation (up to 28 days)
Yes / No
In hospital mortality (up to 90 days) Yes / No
Adverse events Yes / No
Duration in hours of any form of respiratory support
(mechanical ventilation, NIPPV, HFNC, standard oxygen)
Yes / No
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(Continued)
Length of stay (ICU and hospital) Yes / No
Degree of atelectasis on radiological examination Yes / No
Positive end expiratory pressure measured at the pharyngeal level
(cmH2O)
Yes / No
Oxygenation (PaO2/FiO2 ratio, PaO2, SaO2 and SpO2) Yes / No
Carbon dioxide clearance (PaCO2 and pCO2) Yes / No
Respiratory rate Yes / No
Work of breathing (joules per litre) Yes / No
Patient reported dyspnoea Yes / No
Patient reported comfort Yes / No
Patient reported mouth dryness Yes / No
Patient refusal to continue with treatment Yes / No
Cost comparison of treatment (in Australian dollars) Yes / No
DETAILS OF OUTCOMES INCLUDED IN PAPER
Cut and paste for each included outcome
(Insert outcome name here)
Description as stated in report/paper Location in text
Outcome name as stated in paper
Unit of measurement
Time points measured
Time points reported
Person measuring/reporting
Is outcome/tool validated? Yes/No/Unclear
Missing data
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(Continued)
Power
Notes: Notes:
7. Results
Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.
Dichotomous outcome
Description as stated in report/paper Location in text
(pg & fig/table)
Comparison
group/s
Outcome
Subgroup
Time point mea-
sured
Results
(add more compar-
ison groups here if
necessary)
Intervention Comparison
No. events No. participants No. events No. participants
No.missing partic-
ipants and reasons
No. partic-
ipants moved from
other group/s and
reasons
Any other results
reported
Statistical methods
used and appro-
priateness of these
methods (e.g. ad-
justment for correla-
tion)
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(Continued)
Reanalysis
required? (specify) Yes/No/Unclear
Reanalysis
possible? Yes/No/Unclear
Reanalysed results
Notes: Notes:
Continuous outcome
Description as stated in report/paper Location in
text
(pg & fig/ta-
ble)
Comparison group/s
Outcome
Subgroup
Time point measured
Post-intervention or
change from baseline?
Results Intervention Comparison
Mean SD (or other
variance)
No. partici-
pants
Mean SD (or other
variance)
No. partici-
pants
No. missing partici-
pants and reasons
No. par-
ticipants moved from
other group and rea-
sons
Any other results re-
ported
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(Continued)
Statistical methods
used and appropriate-
ness of these methods
(e.g. adjustment for corre-
lation)
Reanalysis required?
(specify) Yes/No/Unclear
Reanalysis possible?
Yes/No/Unclear
Reanalysed results
Notes: Notes:
8. Other information
Description as stated in report/paper Location in text
(pg & fig/table)
Key conclusions of study authors
References to other relevant studies
Correspondence required for further
study information (from whom, what, and
when)
Notes: Notes:
Appendix 8. Quality assessment form
Allocation of Intervention Comments
Method used to generate group allocation
Quality of group allocation Yes/No/Unclear
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(Continued)
Allocation Concealment
Method used to conceal allocation
Quality of allocation concealment Yes/No/ Unclear
Blinding
Participant Yes/No /Unclear
Outcome assessor Yes /No/Unclear
Other - Specify: Yes/No/Unclear
Intention-to-treat
Intention-to-treat analysis was applied to
all
participants entering study
15% or fewer excluded
Not analysed as intention-to-treat
Unclear
Incomplete outcome data Comments
Was outcome data complete?
Primary Outcome Yes/No/Unclear
Secondary Outcome 1 Yes/No/Unclear
Secondary Outcome 2
(add more rows if necessary)
Yes/No/Unclear
Reporting bias
Have all stated outcomes been fully re-
ported?
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(Continued)
Primary Outcome Yes/No/Unclear
Secondary Outcome 1 Yes/No/Unclear
Secondary Outcome 2
(add more rows if necessary)
Yes/No/Unclear
Other potential sources of bias
Are there any other potential threats to va-
lidity?
Imbalances of participants characteristics at
baseline
Crossover studies (Refer 16.4.3 inCochrane
Handbook (Higgins 2011))
Yes/No/Unclear
Yes/No/Unclear
Other (Refer 8.15.1.5 in Cochrane Hand-
book (Higgins 2011))
Yes/No/Unclear
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We included all three primary outcomes in the ’Summary of findings’ table. In the protocol, we had previously stated that we
would include the following outcomes in the ’Summary of findings’ table: failure of treatment, as indicated by the need for NIPPV or
invasive ventilation; duration in hours of any form of respiratory support; length of ICU stay; degree of atelectasis on radiological
examination; oxygenation; carbon dioxide clearance; and patient-reported outcomes. In this review, we included the following
outcomes in the ’Summary of findings’ table: failure of treatment, as indicated by the need for NIPPV or invasive ventilation; in-
hospital mortality; adverse events; length of ICU stay in days; oxygenation; and the patient-reported outcome - comfort.
• We did not perform a sequential meta-analysis for the primary outcome of failure of treatment.
• We did not perform subgroup analyses for age, BMI, aetiology of acute respiratory failure, obstructive sleep apnoea, or flow rates
of HFNC owing to lack of studies with required detail.
• We did not perform sensitivity analysis on study design (randomized vs quasi-randomized studies) nor on missing data owing to
lack of detail or insufficient studies.
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